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1. ABSTRACT 
1.1 Zusammenfassung 
Das Ziel der vorliegenden Arbeit war die Generierung von hoch-affinen Hai Antikörper vNAR 
Domänen, die verschiedene krankheitsrelevante Antigene adressieren. Hierfür wurde zunächst das 
natürliche IgNAR V Domänen Repertoire des Bambushais (Chiloscyllium plagiosum) charakterisiert 
und Kenntnisse hieraus dienten als Grundlage für die Etablierung einer Komplementaritäts-
bestimmenden Region 3 (CDR3)-randomisierten Typ IV vNAR Hefeoberflächendisplay Bibliothek. 
Mittels Bibliothekendurchmusterung wurden verschiedene Antigen-bindende vNAR Domänen isoliert 
und hinsichtlich ihrer Affinität charakterisiert. Mit diesem Verfahren generierte Binder wiesen 
moderate Affinitäten, im dreistellig nanomolaren bis mikromolaren Bereich, für das jeweilige Antigen 
auf. 
Für die Optimierung der Antigen-bindenden vNAR Domänen wurde eine neuartige Methode zur 
Affinitätsmaturierung etabliert, welche auf der Diversifikation der CDR1 der angereicherten Antigen-
bindenden Varianten beruht.  Durch die Konstruktion von Unterbibliotheken, in denen fünf Reste der 
CDR1-Schleife randomisiert wurden, sowie durch deren Durchmusterung mit signifikant reduzierten 
Antigenkonzentrationen wurden Affinitäts-verbesserte Klone identifiziert. Deren Affinitäten, bestimmt 
mittels Hefedisplay, waren im Vergleich zu den parentalen Molekülen, isoliert nach initialer 
Bibliothekendurchmusterung, erheblich optimiert.   
Darüber hinaus wurden verschiedene vNAR Domänen als lösliche Proteine produziert und sorgfältiger 
hinsichtlich ihrer Affinität, mittels Biolayer Interferometrie, sowie in Bezug auf deren Stabilität, 
mittels thermal shift assays, charakterisiert. In diesem Zusammenhang ergab sich eine starke 
Korrelation zwischen den durch Hefeoberflächendisplay kalkulierten Affinitäten sowie den 
Affinitäten, bestimmt mit löslichen vNAR Domänen. Weiterhin wiesen alle produzierten vNAR 
Domänen eine hohe Thermostabilität auf. Ferner wurde eine EpCAM-bindende, affinitätsoptimierte 
IgNAR V Domäne als Fc-Fusion in Säugerzellen exprimiert. Durch die Charakterisierung dieser 
Variante mittels Biolayer Interferometrie konnte gezeigt werden, dass die Formatierung als Fc-Fusion 
zu einer moderaten, aber dennoch signifikant verbesserten Affinität um den Faktor von drei führt, 
vermutlich bewirkt durch Aviditätseffekte.  
Des Weiteren wurde im Rahmen dieser Arbeit eine neue Antigenbindestelle in der variablen Domäne 
von IgNAR generiert. Dies wurde durch die Diversifizierung der hypervariablen Schleife 2 (HV2) der 
IgNAR V Domäne und Bibliothekendurchmusterung erreicht.  Ein EpCAM-spezifischer vNAR wurde 
als Ausgangsmaterial genutzt und neun Aminosäurereste wurden in HV2 randomisiert. 
Zielmolekül-spezifische Klone, welche ein neues HV2-mediiertes Paratop beinhalteten, wurden gegen 
cluster of differentiation 3 Untereinheit ε (CD3ε) sowie gegen den humanen Fcγ-Teil isoliert, wobei 
die hohe Affinität gegen EpCAM erhalten blieb. Folglich wurden somit bi-spezifische vNAR 
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Moleküle generiert. Im Wesentlichen konnte mittels Hefeoberflächendisplay gezeigt werden, dass ein 
neues Paratop in das vNAR Gerüst konstruiert werden konnte, welches unabhängig von der üblichen 
Antigenbindestelle, bestehend aus CDR3 und CDR1, fungiert. 
 
1.2 Abstract 
The aim of the work presented herein was the generation of high-affinity shark vNAR domains 
targeting different disease-related antigens. For this, the natural IgNAR V domain repertoire of the 
bamboo shark (Chiloscyllium plagiosum) was analyzed and in analogy to these findings, a semi-
synthetic complementarity determining region 3 (CDR3)-randomized Type IV vNAR library was 
constructed for yeast surface display. By library screening against several disease-related antigens 
multiple different antigen binding vNAR domains were isolated and characterized in terms of affinity, 
revealing moderate affinities in the triple-digit nanomolar to micromolar range.  
For optimization of antigen binding vNAR domains, a new methodology for affinity maturation was 
established that relies on the diversification of CDR1 of target-enriched binders. Sublibraries were 
constructed in which five residues of the CDR1 loop were randomized and affinity-enhanced vNAR 
domains were identified by sublibrary screening using significantly decreased target concentrations. 
Affinities determined using yeast surface display revealed substantially affinity-optimized clones 
compared to parental molecules, obtained from initial library sorting.  
Additionally, several vNAR domains were produced as soluble proteins and characterized more 
meticulously in terms of affinity using bio-layer interferometry and in terms of stability via thermal 
shift assays. In this respect, affinities calculated by yeast surface display strongly correlated with 
affinities determined for soluble IgNAR V domains. Moreover, all produced vNAR variants exhibited 
high thermostability. Besides, an EpCAM-binding, affinity-matured vNAR domain was expressed as 
Fc-fusion protein in mammalian cells. Characterization of this formatted variant using biolayer 
interferometry resulted in a moderately, but significantly enhanced affinity by the factor of three, 
presumably through avidity-effects. 
Furthermore, the generation of a new antigen-binding site into the IgNAR variable domain was also in 
the scope of this work. This was achieved through the diversification of hypervariable loop 2 (HV2) of 
the IgNAR V domain and library screening. An EpCAM-specific vNAR was used as starting material 
and nine residues in HV2 were randomized. Target-specific clones comprising a new HV2-mediated 
paratope were isolated against cluster of differentiation 3ε (CD3ε) and human Fcγ while retaining high 
affinity for EpCAM, resulting in bi-specific vNAR molecules. Essentially, it was demonstrated that a 
new paratope can be engineered into the vNAR scaffold that acts independently from the original 
antigen-binding site, composed of CDR3 and CDR1, as verified by yeast surface display.  
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2. INTRODUCTION 
Vertebrates, invertebrates as well as all multicellular organisms are constantly exposed to microbial 
pathogens and potentially life-threatening infections. However, those hosts are usually capable of 
defending themselves against pathogenic substances by their ability to recognize infectious microbes 
and via inducing an adequate defense response.[1,2] The evolutionary ancient form of defense 
mechanisms shared by most - if not all - multicellular organisms is referred to as innate immunity. In 
addition, jawed and jawless vertebrates possess highly specialized and antigen-specific defense 
mechanisms in order to overcome exposure to severe pathogens. This kind of defense is called 
adaptive immunity. The innate immune systems as well as adaptive immunity are as extensively 
described by Medzhitov and co-workers [3,4]  
Innate immunity can further be subdivided into constitutive and inducible defense mechanisms.[1] 
Constitutive defense mechanisms e.g. barrier functions, antimicrobial peptides and enzymes are 
present at sites of continuous interactions with microbes and their defense responses are strictly 
directed to target potential pathogens but not host cells. Inducible defense requires recognition of the 
invader and ultimately results in triggering cascades activating inflammatory responses and killing of 
the potential pathogen.[5,6] Key elements for the recognition of invading organisms are so called 
pathogen recognition receptors (PRRs). These receptors can either be expressed on the cell surface, in 
intracellular compartments or can be secreted.[7] PRRs recognize structural elements only produced 
by microbial pathogens, referred to as pathogen-associated molecular patterns (PAMPs). PAMPs 
represent conserved molecular patterns, often shared by large groups of microorganisms.[1,8] 
Hallmarks of PRRs are that those molecules are usually fixed in the genome, i.e. no rearrangement 
events occur to produce a very diverse set of receptors. Furthermore, there is no clonal distribution, 
hence, all cells of a particular class usually express identical PRRs. Additionally, PRRs are present 
before the exposure with the invader. As a consequence, effector functions are immediately activated 
upon induction of the receptor.[5]  
Central elements of innate immune mechanisms are present in invertebrates and also in vertebrates. 
However, it is supposed that the variability and diversity is much higher among invertebrates, which in 
contrast to vertebrates are unable to respond in an antigen-specific manner.[6] Essentially, according to 
Flajnik and Du Pasquier, the invertebrate innate immune system varies greatly in the level of 
complexity and in its forms of defense among different organisms and invertebrates immunity evolves 
rapidly.[9] Within the animal kingdom several hosts have evolved their own special mechanisms of 
defense and it is not always that easy to clearly discriminate between innate and adaptive immunity.[9-
11]  
One striking example is the hypervariable gene that encodes for Dscam molecules (Down syndrome 
cell adhesion molecule) in insects, which is involved in the innate immune system.[12] A diverse set of 
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more than 1.9 x 10
4 
different Dscam molecules with a molecular weight of approximately 210 kDa can 
be generated by alternative splicing. Dscams function as PRRs and it was shown that a knock-down of 
Dscam expression impairs bacterial uptake by insects.[10-12]  
Another peculiarity is found in snails which express a very diverse family of fibrinogen-related 
proteins (FREPs).[13] FREPs consist of one or two N-terminal Ig superfamily domains followed by a 
C-terminal fibrinogen domain. FREP gene expression is up-regulated following infection and FREP 
proteins are able to bind a wide range of pathogens displaying carbohydrates on their surfaces. FREPs 
mediate several different immune effector functions e.g. agglutination, phagocytosis and the release of 
toxic oxygen radicals. [11] FREP genes diversify somatically by gene conversion and/or somatic 
hypermutation as well as alternative splicing.[9] Interestingly, as described by Flajnik und Du 
Pasquier, somatic mutations are associated with adaptive immunity which is exclusively ascribed to 
vertebrates.[9]    
Hallmarks of the adaptive immune response are antigen-specific responses and memory. Key elements 
of the jawed vertebrate’s adaptive immune system are B-cell receptors (BCRs), T-cell receptors 
(TCRs) and MHC molecules.[14] However, in contrast to this, the jawless vertebrate’s (lampreys and 
hagfish) acquired immunity relies on a unique class of antigen receptors referred to as variable 
lymphocyte receptors (VLRs).[15,16] VLRs are structurally unrelated to BCRs and TCRs and are 
composed of highly diverse leucine-rich repeats (LRRs) sandwiched between amino- and carboxy-
terminal constant LRRs. There are three different types of VLRs, called VLRA, VLRB and VLRC. 
VLRA and VLRC are expressed on T-cell like VLRA+ and VLRC+ cells. VLRB+ cells expressing 
VLRB are B-cell like and differentiate into VLRB secreting plasma cells after antigen stimulation.[14] 
The theoretical diversity of the VLRA and VLRB repertoire is estimated to vary between 10
14
 and 10
17
 
different receptors, respectively, thus it is comparable to the potential diversity of TCR and BCR 
repertoires in mammals.[17] The jawless adaptive immune system and structural as well as functional 
features of VLRs are elegantly described elsewhere.[14,17] 
In addition to the above described peculiarities, the jawed vertebrate’s immune system also comprises 
several peculiar features e.g. heavy-chain only antibodies or antibodies with ultra-long CDR3-regions, 
some of which will be discussed in this work.[18,19]  
Typically antibody molecules are composed of heavy chains and light chains. However, camelids and 
the cartilaginous fish possess natural antibodies composed only of heavy chains (HCAbs).[20,21] The 
antigen-binding sites i.e. paratopes of those exceptional molecules are formed by only one single 
domain, referred to as VHH and vNAR, respectively. Due to an increased frequency of polar and 
charged amino acids at the solvent-exposed regions corresponding to the hydrophobic VH-VL 
interface of conventional antibodies, vNAR and VHH domains are highly soluble.[22] Intriguingly, 
HCAbs naturally complement the conventional repertoire of the aforementioned species. Whereas 
classical antibodies usually have planar or concave antigen-binding sites, vNAR- and VHH-domains 
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possess a wide variety of different loop structures. This leads to a drastically expanded repertoire of 
available paratopes capable of accessing and binding to more cryptic epitopes and catalytic clefts of 
enzymes that are intractable to classical antibodies.[23-25] Due to this paramount therapeutic and 
diagnostic attribute of VHHs and vNARs, there is a strong effort within the scientific community to 
utilize these domains for medical and biotechnological applications. While camelid VHH domains 
have proven to be successful in early phase clinical trials,[26] the engineering of vNAR domains - 
which are the main focus of this work - for biomedical applications is at an earlier stage. 
 
2.1 Antibodies as key players in the immune system 
Antibodies are part of the adaptive immune system and comprise the humoral immune response. At 
first, antibody molecules are expressed as receptors on the surface of B-cells. It is supposed that the 
immune system gives rise to theoretically more than 10
14
 different B-cells, each producing a unique 
surface bound antibody (B-cell receptor) with a distinct specificity.[27] The process for the primary 
diversification of the antibody repertoire will be shortly discussed in section 2.5.3. Initial interaction of 
a B-cell receptor that specifically binds to the particular antigen provokes a primary response. As a 
consequence and also owing to complex immunological processes that involve parts of the innate and 
of the adaptive immune system, the B-cell starts to secrete the antibody molecule.[2-4] The high 
specificity for the individual antigen combined with Fc-mediated immune effector functions of the 
antibody ultimately causes the elimination of the antigen. After further stimulation with the antigen the 
secondary antibody response is characterized by high-affinity antibodies of other classes, mediated by 
processes referred to as somatic hypermutation and isotype switching, which will not be discussed 
within the scope of this work.[28-30] In humans there are five isotypes of antibodies categorized based 
on their heavy chain constant domains, IgM, IgG, IgA, IgD and IgE. In addition IgG can be divided 
into four subclasses, namely IgG1, IgG2, IgG3 and IgG4 and akin to this IgA can be subdivided into 
IgA1 and IgA2.[31] Essentially, the isotype switch from IgM to another isotype alters effector 
functions,[31,32] which will be discussed in the next chapter. Furthermore the isotype determines the 
pharmacokinetic profile of the antibody as well as the localization of the antibody within the body.[32] 
Because most of the therapeutic antibodies in the clinic are of the IgG isotype,[33,34] this class will be 
described more in detail.  
 
2.2 Structure and function of antibodies 
IgG antibodies are structurally complex, large hetero-tetrameric proteins (approximately 150 kDa) 
comprising two identical heavy chains and two identical light chains (Fig. 1). Each heavy chain 
consists of three constant domains, followed by the N-terminal variable domain. The light chain is 
composed of one constant domain and one N-terminal variable domain. The two identical antigen-
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binding sites, i.e. paratopes, are composed of one variable domain of the heavy chain and one variable 
domain of the light chain, respectively.[34] Within each variable domain, three hypervariable loops, 
called complementarity determining regions (CDRs), mediate antigen binding.[31] Hence, a total 
number of six CDRs (three of the heavy chain and of the light chain, respectively) may contribute to 
antigen binding. Antibodies bind antigens via non-covalent interactions. Antibody molecules can act 
directly on targeted antigens, e.g. the antigen-antibody interaction can neutralize the function of the 
antigen or block downstream-signaling of a cell-surface-receptor on a targeted cell.[35-37]  
 
Figure 1. Structural features of IgG antibody shown as surface representation (top) as well as ribbon and schematic 
representation (bottom). Individual domains are colored as indicated in the schematic representation; hinge region is 
colored yellow; glycans not shown. IgG model is based on pdb entry 1IGT.[38] Picture rendered with POV-Ray 
(www.povray.org/). Figures 1 – 6 were constructed in close cooperation with Martin Empting and have recently been 
published.[39] 
 
In addition, antibodies are able to act indirectly via effector functions. Such functions are mediated by 
the Fc-part of the molecule (i.e. CH2 and CH3 of each chain of IgG). Binding to Fcγ receptors, for 
instance, that are expressed on almost all cells of the immune system, can result in activation of cells 
and effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) mediated by 
natural killer cells, phagocytosis of immune complexes or the release of inflammatory 
mediators.[32,40] Essentially, Fc receptors link the humoral components of the adaptive immunity 
with cellular components of immunity. On the same cells, there are activating and inhibitory receptors 
co-expressed. Balanced signaling through these keeps the immune response in normal limits.[41] The 
main interaction site of IgG with Fcγ receptors is located in the lower hinge-region (Fig. 1, yellow) 
and in the adjacent sites of CH2 (Fig. 1, light red).[32,42] Moreover, a glycosylated Asn-297 in CH2 
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of IgG is critical for Fcγ receptor binding. Finally, also residues of CH3 are important for this 
interaction.[32] 
Another receptor, referred to as neonatal Fc receptor (FcRn) is responsible for the delivery of IgG 
across the maternofetal barrier and also for controlling the catabolism of this isotype. The mechanism 
that ensures the integrity of both processes is the ability of IgG to interact with FcRn in a pH-
dependent manner. IgG is bound by FcRn after internalization in the endosomal compartment at mild 
acidic conditions (pH 6.0 – 6.5) and released at pH 7.0 – 7.4 on the plasma membrane and thus 
recycled as well as transported within and across cells. [32,43] Essential for FcRn interaction, hence, 
for transcytosis as well as IgG-recycling are residues located at the interface of domains CH2 and CH3 
of the Fc-part. It needs to be mentioned that there are also proteins and receptors that interact with Fc-
parts of other antibody isotypes. Such interactions can also mediate effector functions or mediate the 
transport of IgA and IgM.[32] 
In addition to FcR-binding, IgG molecules (as well as other isotypes) interact with several other 
proteins e.g. components of the complement systems (C1q, C3b, C4b) and complement-related 
anaphylotoxins. Herein only the interaction with C1q is described. A comprehensive review about Fc-
mediated interactions and effector fuctions can be found elsewhere.[32] IgG as well as IgM molecules 
are able to induce the classical pathway of the complement system by their ability to bind to C1q. As 
monomers IgG molecules display very weak affinity to C1q and are consequently unable to activate 
the complement cascade, which ultimately leads to the formation of the membrane attack complex and 
the elimination of the targeted cell. This process is named complement-dependent cytotoxicity (CDC). 
However, owing to polyvalent interactions, IgG aggregation i.e. multivalent interactions of several IgG 
molecules increases apparent affinity significantly, resulting in the activation of the complement 
cascade. C1q binding to IgG is primarily due to structural features of CH2 of IgG and multiple 
residues are involved in the interaction.[32,44]  
                                                                                              
2.3 Beneficial attributes and potential limitations of antibodies for biomedical 
applications  
Parts of this section were recently published.[39] Nowadays, biological entities are one of the main 
drivers of sales within the pharmaceutical market, with growth rates that substantially succeed those of 
the overall pharmaceutical sector [45]. Within this group of new biological entities, monoclonal 
antibodies (mAbs) are among the most successful and frequently used biotherapeutics. mAbs are the 
highest selling class of biologics, followed by hormones, growth factors and fusion proteins, 
respectively.[45] Annual growth rates of mAbs are constantly increasing within the last years,[45-47] 
exceeding 10 % for the first time in 2011 [46] and forecasts predict an ongoing trend.[48] The total 
number of 40 US Food and Drug Administration (FDA) - approved antibodies with several 
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blockbuster agents amongst them [48] and a continuously growing number of more than several 
hundred of mAbs in clinical development is clearly emphasizing their paramount therapeutic 
value.[45,49,50]  
However, under certain circumstances the therapeutic and diagnostic efficacy of monoclonal 
antibodies might be limited due to inherent attributes, e.g. structural complexity and large size. The 
paratope of conventional antibodies can be restricted in its ability to access certain epitopes, e.g. 
recessed cryptic epitopes or active sites of enzymes.[18,51,52] Furthermore, the mobility, i.e. tissue 
penetration, of classical antibody molecules is constrained by their large size.[53] For in vivo tumor 
imaging purposes, the slow blood clearance of conventional antibodies poses a problem due to their 
extended plasma half-life.[54] Slow tumor penetration as well as nonspecific uptake by healthy tissues 
may represent further drawbacks of conventional antibodies in molecular imaging.[55-58] Moreover, 
most complex diseases, e.g. cancer, HIV and inflammatory diseases are usually multifactorial in 
nature. Thus, tumor cells often up-regulate different growth-promoting receptors that can act either 
independently or crosstalk intra-cellularly.[59] Targeting of one receptor by a mono-specific antibody 
may result in resistance which for instance may be associated with the up-regulation of alternative 
receptors as well as pathway switching.[60] 
To address these issues and to increase the overall therapeutic and diagnostic efficacy, next-
generation-antibodies (e.g. bi-specific antibodies, antibody-drug-conjugates, antibody-cytokine-
conjugates), antibody fragments and non-immunoglobulin based protein scaffolds have been 
engineered and developed, as extensively described elsewhere.[61-70] Because bi-specific antibodies 
are of particular relevance for this work, the rationale for their design as well as different formats will 
be discussed in the following section.  
 
2.4 Bi-specific antibodies 
There is a plethora of rationale for the generation of bi-specific antibody molecules (bsAbs) 
simultaneously binding two different antigens with their two antigen-binding sites. As aforementioned, 
many diseases are multifaceted in their behavior.[59,71] Crosstalk of receptor tyrosine kinases, for 
instance, can induce tumor resistance to (mono-) therapy. For example, there is clear evidence that 
tumor resistance to an inhibitor, i.e. Cetuximab of the Epidermal Growth Factor Receptor (EGFR) is 
caused by the up-regulation of other human epidermal growth factor receptor (HER) members.[72,73]  
Furthermore crosstalk between insulin-like growth factor receptor 1 (IGF-1R) and EGFR may mediate 
resistance to one another.[72,74,75] Besides, also overexpression as well as activation of the 
hepatocyte growth factor receptor (cMET) is known to induce tumor resistance to HER member 
blockage.[73] bsAbs can overcome the limitation of mono-specific antibody based therapy and find 
application in multifactorial diseases because those molecules can be engineered to address multiple 
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epitopes of the same target or sites on different targets within one single entity.[71,76,77] In addition, 
selective targeting of a defined cell population characterized by the overexpression of two antigens can 
improve safety (especially for bi-specific antibody-drug conjugates) and efficacy. Other approaches for 
the design of bi-specific antibodies comprise the transport of the drug to a specific tissue e.g. delivery 
across the blood-brain barrier as well as the recruitment of effector cells.[78] In the latter respect, 
targeting a tumor-associated antigen as well as CD3 of cytotoxic T-lymphocytes can elicit effective 
tumor killing.[79] Besides, targeting specific Fcγ receptors can engage natural killer cells and myeloid 
effector cells to eliminate tumor cells.[80] Another rationale for bsAbs is the utilization of such 
molecules for the delivery of payloads such as imaging agents for diagnostic applications. In this pre-
targeting application, one antigen-binding site of the bi-specific molecule interacts with the clinical 
target, the other arm is able to bind to a detection moiety, that is injected once the unbound bsAb has 
cleared from the blood-stream.[71,80]   
The first bsAb that has been approved for therapy in the European Union in April 2009 was 
Cetumaxomab for the treatment of patients with malignant ascites.[81] Cetumaxomab is a bsAb, 
simultaneously targeting the epithelial cell adhesion molecule (EpCAM) which is expressed on a 
multitude of tumors and CD3 on T-cells for the redirection and activation of T-cells at the tumor site 
resulting in significant tumor lysis. This therapeutic entity is a combination of half of an EpCAM-
specific mouse IgG2a and a half of a CD3-specific rat IgG2b.[82]  
To this date, there is a multitude of different bsAb formats targeting multiple different antigens in 
clinical development.[79,80] bsAb formats include but are not limited to trifunctional hybrid 
antibodies (e.g. Cetumaxomab), tandem scFvs such as bi-specific T-cell engagers (BiTEs), bispecific 
diabodies as well as the Dock and Lock (DNL) platform.[79,82] Moreover, different methodologies 
have been established to design human full-length IgG-like antibodies such as knob-into-holes[83], 
SEED[84] or Luz-Y[85] for the hetero-dimerization of the heavy chain as well as CrossMab 
technology for correct association of a respective light chain to its corresponding heavy chain.[86] 
Essentially, bsAbs represent a whole new repertoire for therapeutic applications and in contrast to  
antibody mixtures there is no need for time-consuming and costly separate single agents trials followed 
by combination trials.[78,82]   
 
2.5 The New Antigen Receptor (IgNAR) 
A modified version of this chapter was recently published in a review on shark antibodies.[39] The 
cartilaginous fish (sharks, rays, skates and chimaeras) express three different isotypes of antibodies, 
IgM, IgNAR and IgW.[87,88] IgNAR was first identified in the serum of the nurse shark 
(Ginglymostoma cirratum) in 1995 by Flajnik and co-workers.[21] It is a homodimer of heavy chains 
devoid of light chains. Each chain of the secretory form consists of one variable domain followed by 
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five constant domains, the last four being homologous to IgW constant domains.[89] Serum IgNAR 
levels range from ~ 0.1 mg/ml to 1 mg/ml.[90] 
Based on atomic resolution structural data as well as small-angle X-ray scattering, Buchner and co-
workers were able to develop a structural model of the complete IgNAR molecule (Fig. 2).[91] IgNAR 
is a heavy-chain only homodimer. Each heavy chain consists of five constant domains, followed by the 
N-terminal variable domain. Within the molecule, domains C1 and C3 of each chain cause 
dimerization of IgNAR. Despite the lack of a canonical hinge region, the variable domains are spaced 
sufficiently wide for binding multiple epitopes, facilitated by the wide angle of the C1 dimerization 
interface. A small angle between both C3 domains induces the formation of a narrow stalk for the 
IgNAR molecule. However, flexibility of the stalk is induced by a disulfide-bridged linker that 
connects domains C3 and C4. The heavy-chain only molecule is kinked approximately in the middle of 
the molecule, at the location of the flexible linker, causing its characteristic shape. Whether any 
effector functions are mediated by the constant region of IgNAR is currently unresolved.[51] Finally, it 
is important to note that the structure of C5 shown in Figure 2 is completely hypothetical (Fig. 2). 
This is due to a lack of structural data on this domain, which does not exhibit a fold, neither as isolated 
recombinant protein nor within a C4-C5 construct.[91]  
 
Figure 2. Structural features of shark IgNAR antibody formats shown as surface representation (Top) as well as ribbon and 
schematic representations (Bottom). Individual domains are colored as indicated in the schematic representation. 
Coordinates of intact IgNAR including the hypothetical structure of IgNAR C5 domain were generously provided by Prof. 
Dr. Michael Sattler and Dr. Janosch Hennig (see Feige et al.).[91] Picture rendered with POV-Ray (www.povray.org/). 
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2.5.1 Absence of a light chain partner 
The homodimer IgNAR displays several unique features that are responsible for the inhibition of a 
potential light chain pairing. At the typical VH-VL interaction site, there is poor conservation of 
residues that mediate this association in mammals.[92] Instead these typically hydrophobic amino 
acids are frequently replaced by polar or charged residues.[22] For classical antibodies, a special 
mechanism ensures the formation of heavy- and light-chain pairing. In the endoplasmic reticulum, the 
heavy chain is trapped by an Ig-binding protein (BiP) via interaction with the CH1 domain. For the 
release, a light chain must displace BiP, and, consequently, only heavy- and light-chain paired 
antibodies are secreted.[22,93] Flajnik and co-workers hypothesized that during evolution, a vNAR-D-
J cluster recombined with an IgW cluster in a way that the IgW cluster lost its V-D-J segments and the 
first C exon.[94] Indeed, the C1 domain of IgNAR is somewhat similar to the CH2 domain of IgW and 
may be derived from this domain.[95] BiP- and L-chain-interaction sites are consistently missing in 
the C1 domain of IgNAR, as elegantly reviewed by Flajnik and colleagues.[22]  
 
2.5.2 The variable domain of IgNAR – structural features  
The variable domain of the New Antigen Receptor shows homology to the T-cell receptor (TCR) Vα 
and also is found as a variable domain in the NAR-TCRδ.[96] It also displays sequence homology to 
immunoglobulin Vκ domains, whereas structurally it is related to Vα, Vλ, and VH domains.[24] 
Moreover, since vNAR domains share structural features of cell adhesion molecules, it was suggested 
that IgNAR evolved from a cell-surface receptor, clearly distinguishing it from VHH, which evidently 
arose from an IgG lineage.[22,97] vNAR belongs to the Ig superfamily, and accordingly it has a 
β-sandwich fold. However, compared to mammalian V domains, this fold only consists of 8 instead of 
10 β-strands due to the deletion in the framework2-CDR2-region (Fig. 3).  
With a molecular mass of ~ 12 kDa, the vNAR domain is the smallest antibody-like antigen binding 
domain in the animal kingdom known to date.[24,51] As a consequence, contrary to mammalian 
variable domains, vNAR domains have only two complementarity determining regions CDR1 and 
CDR3 (Fig. 3, Fig. 4). The diversity of the primary vNAR repertoire is predominantly found in CDR3. 
High rates of somatic mutation after antigen contact are observed in CDR1, at the CDR2 truncation 
site, where the remaining loop forms a belt-like structure at the bottom of the molecule and in a loop 
that corresponds to HV4 in TCRs. Accordingly, these mutation-prone regions have been named HV2 
and HV4, respectively (Fig. 4).[98] Indeed, it was shown that somatic mutations within HV4 can 
contribute to antigen binding.[99]  
Despite having a reduced number of possible antigen binding loops (four across a single chain) 
compared to conventional antibodies (six loops across two chains), vNAR domains bind antigens with 
surprisingly high affinities.[100,101] Even from primary repertoires, where antigen binding is solely 
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mediated by CDR3, vNAR molecules can be obtained against a given antigen with affinities in the low 
nanomolar range.[99,100] The highest recorded affinities for vNAR domains, however, have been 
observed after immunization with an anti-albumin binding domain, achieving picomolar levels of 
affinity.[101]  
 
Figure 3. Comparison of VH (left; from pdb entry 1IGT) and vNAR (right, from pdb entry 2COQ) binding domains 
depicted as ribbon representation as well as an overlay of both structures (middle).[25,38] CDR1 and CDR3 are shown in 
grey. Two beta strands and CDR2 of the VH domain are highlighted in orange. These structural elements are absent in the 
vNAR domain which possesses HV2 and HV4 (both highlighted in blue), instead. Disulfide bonds are shown as yellow 
sticks. Picture rendered with POV-Ray (www.povray.org/). 
 
Based on the number of non-canonical cysteine residues, which are not found in classical variable 
domains, vNAR molecules have been categorized into four types (Fig. 4).[24,25,99,102,103] The 
classical Ig canonical cysteines, which stabilize the immunoglobulin fold via a disulfide bond, are 
common to all types. Type I variable domains carry extra cysteines in framework regions 2 and 4, and 
consequently, an even number of partner cysteine residues in CDR3. The determination of the crystal 
structure of a type I vNAR in complex with lysozyme revealed that both non-canonical framework 
cysteines each form disulfide bonds with those of CDR3, causing this loop to be held tightly into the 
direction of HV2.[24] Thus far, type I variable domains of IgNAR have only been identified in the 
nurse shark, Ginglymostoma cirratum.[51]  
Type II domains differ from type I by means of an additional cysteine in CDR1 and in CDR3, 
respectively, resulting in an intra-molecular disulfide bond that brings both loops in close vicinity. 
However, it lacks both cysteine motifs that anchor CDR3 to the framework in type I vNAR. As a 
consequence, the CDR3 region forms a protrusive ‘finger-like’ structure that is predisposed to binding 
into pockets or grooves, e.g. the active site of enzymes.[25] According to this, it has been shown for 
both types that active site clefts can be penetrated by the antigen binding loops.[24,99]  
Another type, termed type III, is expressed in neonates at high frequencies.[25,102] Akin to type II 
domains, this isotype is characterized by an additional non-canonical cysteine in CDR1 and CDR3, 
respectively. However, in contrast to type II, type III domains comprise a restricted CDR3 diversity 
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that is highly similar in amino acid composition and length as well as a conserved tryptophan residue 
in CDR1 positioned adjacent to the disulfide bridge between both loops. Based on the limited CDR3 
diversity it is tempting to speculate that type III vNARs evolved as a consequence of exposure to a 
common pathogen in early development of sharks or that it may play a role in regulatory processes 
during the development of the shark’s immune system.[25,51,102]  
Type IV domains differ from all described vNAR types in that they lack non-canonical disulfide bonds 
as found in all other vNAR types.[101,103] Therefore, the topology of the paratope of type IV variable 
domains is more flexible and not physically constrained. Type IV domains are also referred to as type 
IIb, according to Streltsov et al. and Liu et al.[97,104] In addition, type IV domains with an invariant 
tryptophan residue in CDR1, similar to type III, have been identified.[105] Besides type III, all types 
of the vNAR domain give rise to high-affinity binders.[24,99,101,106]  
 
Figure 4. Different types of IgNAR V domains. Variable domains are categorized based on the presence or the absence of 
non-canonical cysteine residues (black dots). Canonical cysteine residues (white dots) and disulfide bonds (connecting 
lines), conserved tryptophan (W) as well as complementary determining regions (CDR) and hypervariable loops (HV) are 
shown in their relative positions. Ribbon presentations of vNAR domains are depictions of pdb entries 1SQ22 (type I),[24] 
2COQ (type II),[25] and 4HGK (type IV)[103] as well as a modelled type III structure based on 2COQ. The latter was 
generated via homology modeling using YASARA structure.[107] First, vNAR residues of 2COQ were changed to match a 
reported type III sequence (AAM76948 from Streltsov et al.).[25] Then, side chain geometries were optimized followed by 
a two-step energy minimization using the YASARA2 force field.[107] 
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2.5.3 Diversification of the IgNAR repertoire  
In mammals, antibody diversity is generated in a process referred to as V(D)J-recombination. During 
B-cell development, one variable (V) segment, one diversity (D) segment and one joining (J) segment 
are randomly rearranged from a multitude of gene segments of the immunoglobulin heavy chain gene 
cluster to encode the VH domain, which is fused to a gene segment encoding a constant domain.[22] 
Similarly, for light chain generation, one V segment and one J segment are selected by chance from a 
pool of gene segments to produce the variable domain of the light chain that is fused to a CL gene. 
Diversity is further expanded in a process called junctional diversification through imprecise segment 
joining.[108] An additional layer of diversity is introduced by the random arrangement of the heavy 
chain and light chain to complete the expression of the antibody molecule.  
As IgNARs are devoid of light chains, they lack H-L combinatorial diversification. Correspondingly, 
one would expect a dramatically restricted primary repertoire. However, this lack of diversification 
process is at least partially compensated through the diversity achieved within the CDR3 region. 
Whereas mammalian antibody genes are organized in the translocon-format, shark antibody genes are 
exclusively arranged in the cluster-organization (Fig. 5).[24,51,94,99] Nurse sharks comprise four 
IgNAR gene clusters, though only two are expressed in adult life, one encodes type I and one encodes 
type II IgNARs.[24,99] Each IgNAR cluster comprises one V segment, three D segments and one J 
segment and a single set of C segments. Rearrangement occurs solely within this cluster resulting in a 
VD1D2D3J assembly. Hence, four rearrangement processes generate the complete vNAR domain. 
However, the order of rearrangements remains to be determined.[94] The interfaces between the V 
segment, the three D segments and the J segment encode for CDR3. Consequently, diversity in both 
sequence and length of the primary repertoire is nearly entirely found in CDR3.[102,109,110] 
Extensive junctional diversification through N-region addition, P-nucleotide addition, trimming and D-
region rearrangement further expands the heterogeneity of the primary repertoire of 
IgNAR.[24,51,94,111] The type III gene cluster represents an exception within the recombination 
process. As a result of the fusion of the D1 segment and the D2 segment in the nurse shark, only three 
rearrangement events occur, explaining the restricted diversity of this type. In contrast to this, in the 
spiny dogfish the type III IgNAR cluster is not partially germline-joined, indicating that germline-
joining of Ig clusters might be a species-specific event.[112]  
Sharks do not possess conventional germinal centers.  Nevertheless, the initial combinatorial diversity 
which is mainly restricted to CDR3, is further expanded by extensive somatic hypermutation in an 
antigen-driven manner, with mutations clustering to the CDRs.[109] The mutational pattern and 
frequencies of this process are similar to that of mammalian immunoglobulins with a bias for 
transitions over transversions. The mechanism favors the serine codon AGC/T as a hotspot for 
mutations and most of the changes are base substitutions. Surprisingly, base changes often occur in 
tandem, particularly in mutational hotspots and palindromic repeats.[110] It was first shown by Flajnik 
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and co-workers, that after immunization, somatic mutations promoted an incremental increase in 
affinity, giving clear evidence for in vivo affinity maturation in sharks.[24,90,98-100] Furthermore, 
they demonstrated that HV4 is prone to somatic mutations and, even more interesting, these mutations 
can be involved in antigen binding.[99]  
Consistent with the structure of type I and type II IgNARs (Fig. 5), mutations are favored in CDR1 for 
type II vNARs and in HV2 for type I vNARs.[22,24] It is hypothesized that those mutations could 
either directly contribute to antigen binding or they could indirectly have an effect on the paratope 
such as that they stabilize and influence the conformation of the antigen binding CDR3.  
 
Figure 5. Translocon arrangements of immunoglobulin genes in higher vertebrates and cluster configuration of IgNAR 
genes of cartilaginous fish. In the translocon organization there are many variable (V) segments upstream of many diversity 
(D, only for heavy chains) and joining (J) segments that recombine randomly to encode the variable domain of the heavy 
chain or the light chain. IgNAR genes (like all Ig genes of the cartilaginous fish) are organized in the cluster configuration. 
Each cluster contains for the variable domain one V segment, three D segments and one J segment. Recombination occurs 
exclusively within one cluster. H, heavy chain loci; L, light chain loci, C, constant region. 
 
2.5.4 Selection of antigen-specific vNAR domains from shark immune repertoires 
Antigen-specific vNAR domains have been generated from the immune repertoire of a number of 
different shark species, including the nurse shark,[100] the wobbegong shark,[106,113] the spiny 
dogfish,[101,104,114] and the banded houndshark.[115,116] Target-specific clones are generally 
isolated using different display technologies, such as phage display[100,106] or ribosome 
display.[117] There are several distinct strategies for library establishment. Binders can be selected 
from immunized sharks,[100,101] from the naïve shark repertoire,[104] or from a synthetic vNAR 
library,[106,118] where the vNAR molecule serves as a scaffold with randomized loops and from 
semi-synthetic repertoires. Here, additional diversity is included through the randomization of one or 
more antigen binding loops.[114,119] For the most part, immunization is the preferred route to obtain 
high-affinity binders. An additional advantage of immunization is that sharks are evolutionary very 
distant to humans. This greatly reduces the likelihood of immune tolerance that would reduce the 
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induction of target-specific responses when antigens are well conserved across species. Consequently, 
antigen-specific vNAR molecules have been generated with impressive affinities against a multitude of 
different targets via immunization.[100,101,120,121] However, the process of immunization of sharks 
is protracted compared to standard mammalian protocols, and not every species tested has proven 
successful.[101,122] For instance Dooley et al. and also our group were unable to detect an antigen-
specific IgNAR response after the immunization of the small spotted catshark, Scyliorhinus 
canicula.[123]  
Antigen-specific vNAR fragments have also been isolated from non-immunized libraries against a 
plethora of different targets, including viral targets and toxins.[104,114,116,119,124,125] Table 1 
illustrates vNARs selected against therapeutically relevant targets from immunized and non-
immunized origins (Tab. 1).  Surprisingly, binders selected from such libraries often show good 
affinities to their target.[113,114,124,125] Nonetheless, when higher affinities are required, vNARs 
can be optimized using in vitro affinity maturation. To this end, two different methodologies have been 
established. Nuttall and co-workers were able to improve the affinity for an AMA1-specific IgNAR V 
domain using error-prone PCR resulting in a ~ 10-fold enhanced affinity.[125] In a more recent 
approach, the same group employed a mutagenesis system dependent on low fidelity RNA polymerase 
from Qβ bacteriophage to introduce diversity into IgNAR antibody libraries for affinity maturation. 
With this novel strategy they were able to select mutated vNAR molecules with a more than 20-fold 
enhanced affinity compared to the wild type clone.[117]  
 
2.5.5 Therapeutic and diagnostic attributes of vNAR domains  
The tremendous diversity found at the sequence-level of the CDR3-loop of IgNAR, as well as the 
multiplicity of the structural topologies formed by the antigen-binding site of the vNAR domain 
(Fig. 6) render IgNARs promising alternatives to conventional antibodies.[24,25,99] As described 
above, the different types of vNAR domains form, if any, a very diverse set of disulfide bridges. 
Consequently, antigen-specific clones can be selected from a very large, unprecedented repertoire of 
different loop structures.[126] Moreover, this unique paratope-architecture of shark domains seems to 
be predisposed to target clefts of the antigen, whereas recessed epitopes are usually not antigenic for 
conventional antibodies.[22,25,97,127] Indeed, it has been shown that the active site of enzymes and 
clefts can be targeted by vNAR domains.[24,91,99]  
Above all, vNARs exhibit many additional properties that render them interesting for diagnostic and 
therapeutic applications. It has been demonstrated that vNARs are extraordinarily stable 
proteins,[100,104,114,118,121] which is probably a consequence of the harsh physiological 
environment - the blood of sharks contains 350 mM urea - those molecules are exposed to.[105] The 
superior thermal stability and tolerance to irreversible thermal denaturation compared to scFv- and 
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mAb-formats was elegantly demonstrated by Lonsdale and colleagues as well as by Goldman and co-
workers.[104,128]  Concordantly, it has been shown that the C2 and C4 domains of IgNAR are very 
stable. Buchner and co-workers were able to identify structural elements that contribute to their high 
stability. Compared to mammalian constant domains, C2 and C4 domains of IgNAR contain an 
additional salt bridge and an extended hydrophobic core. The transfer of these key elements of 
enhanced stability to a human antibody domain improved its stability significantly.[91]  
The inherent small size of the IgNAR V domain is an additional therapeutic and diagnostic attribute. It 
can be hypothesized that this property leads to a greater mobility with reference to tissue penetration. 
Especially for in vivo imaging, where a high contrast to background ratio is crucial, this feature is 
beneficial, due to an advantageous pharmacokinetic profile, i.e. a much shorter residence time in the 
blood compared to classical antibodies.[54] Furthermore, it is assumed that the small molecular weight 
of the vNAR domain implicates the opportunity to target epitopes otherwise only accessible to small 
molecules.[51]  
 
Figure 6. Examples of CDR3 variability in vNAR domains depicted in ribbon representation. (A) Short loop (type IV, pdb 
entry 4HGK).[103] (B) Large loop with one disulfide constraint (type II, pdb entry 2COQ).[25] (C) Highly constrained 
loop tethered by two cystine motifs (type I, pdb entry 1SQ2).[24] (D) Extended CDR3 forming an α- helical motif (type II, 
pdb entry 2I25).[99] (E) Extended CDR3 forming a two-stranded β-sheet (type IV, pdb entry 2Z8V).[127] (F) Extended 
CDR3 incorporating an amyloid-β p3 fragment (type IV, pdb entry 3MOQ).[129] (G) Overlay of structures A-F. Disulfide 
bonds are shown in yellow. Picture rendered with POV-Ray (www.povray.org/). 
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Table 1. vNAR domains selected against disease related targets. Adapted from ref. [105] 
Target Potential Application KD [nM] Reference 
VHSV Anti-viral - [116] 
TNF-α Endotoxic shock - [130] 
HSA Half-life extension 0.66 [101] 
HBeAg of HBV Anti-viral 53 - 106 [124] 
Ebola virus Immunodiagnostic - [121] 
Cholera toxin Biosensor 83 [104] 
Staphylococcal enterotoxin B Sensor 10.2 - 107 [114] 
Ricin Sensor 299 ± 49 [114] 
Botulinum toxin Sensor 93 - 390 [114] 
AMA1 Malaria diagnosis 15.8 - 358 [117,125] 
VHSV: Viral hemorrhagic septicaemia virus, TNF: Tumor necrosis factor, HBeAg: Hepatitis B e 
antigen, HBV: Hepatitis B virus, HSA: Human serum albumin, AMA1: Malarial apical membrane 
antigen-1. 
 
2.5.6 Re-formatting of vNAR domains 
The simple single chain molecular architecture of vNAR domains affords the benefit of multiple re-
formatting opportunities to tailor the final product for purpose. Many formats have been successfully 
proven, including monomeric, dimeric and trimeric (binding more than one target) in addition to Fc-
based formats, with all demonstrating the inherent flexibility of these domains.[101,103,105,131] 
The small size of vNAR domains leads to rapid renal clearance in vivo and represents a major 
drawback for non-imaging applications such as tumor-targeting. In contrast to this, a small size might 
be advantageous with regard to tumor penetration and ultimately the right format for the individual 
application needs to be determined. Fast glomerular filtration can be circumvented by multimerization 
of single vNAR domains, as shown by Müller et al.[101] Their investigations covered the N- as well as 
C-terminal fusion of a naїve vNAR domain to an anti-human serum albumin (HSA) vNAR originating 
from an immunized shark, isolated via phage display.[132] The fusion constructs retained high-affinity 
binding to HSA and exhibited significantly increased in vivo half-lifes compared to their unconjugated 
parental domains. The size of such dimeric formats is in the range of 25 kDa and compared to other 
antibody fragment formats such as scFvs, achieves double binding site capacity whilst retaining 
   
-19-  
 
increased affinities towards demanding, cryptic epitopes, which is a hallmark of vNAR proteins. In 
addition to dimeric fusions, a trimeric construct comprising the naїve vNAR domain at both termini of 
the anti-HSA vNAR displayed improved pharmacokinetics in in vivo studies in different species.[101] 
In another study conducted by Nuttall and colleagues, several approaches for the generation of bivalent 
shark antibodies with enhanced functional affinity were investigated.[131] Best affinities were 
obtained through C-terminal covalent or domain-mediated linkages. 
As has been shown extensively for rodent mAbs, there is a plethora of rational as well as empirical 
humanization strategies available to reduce immunogenic responses caused by animal-derived 
immunoglobulins.[133-137] Rational design and the grafting of CDR loops of a xenogenic antibody 
onto a suitable human scaffold exhibiting a similar sequence has culminated in the development of 
several blockbuster pharmaceuticals routinely used in the clinic (e.g. trastuzumab, bevacizumab).[138]  
Sequence identity of the IgNAR V domain with mammalian VH regions falls as low as 25 %.[100] In 
order to minimize the immunogenic potential of vNAR domains, Kovalenko and co-workers were able 
to engineer the aforementioned anti-HSA shark vNAR domain[101] by converting more than half of 
the framework amino acids to those of the human germline VK1 sequence DPK9.[103] This sequence 
bears the highest structural resemblance to the corresponding vNAR domain, and concomitantly 
represents one of the most stable human frameworks for downstream development. Determination of 
the binding constants of humanized vNAR variants yielded antigen affinities similar to those of the 
parental construct (14.8 nM vs 13.6 nM for the parental molecule). The opposite approach, to start with 
a structurally related human VH domain and convert that to a vNAR-like domain by clipping the 
CDR2 region, extending CDR3 and introducing stabilizing residues and additional disulfides may also 
be a viable alternative as already shown for the camelization of human VH domains.[139] To enhance 
the expression of humanized vNARs in mammalian cells they were C-terminally fused to human Fc 
domains.[103] This conjugation strategy can also contribute to the formation of dimers due to the 
interactions of two vNAR-Fc conjugates at the respective human constant domains. Fusions to human 
Fc, besides increasing the overall molecular weight and thus counteracting rapid renal clearance, can 
elicit in vivo immune effector functions and ultimately intensify the immune response via antibody-
dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). According to 
Kovaleva et al., the humanized IgNAR V domain variant showed negligible immunogenicity in 
dendritic cell assays.[105] Notably, also no significant immunogenic effects were observed after 
subcutaneous application of the parental, non-humanized anti-HSA vNAR in rodents and non-human 
primates.[101,105] However, it remains to be scrutinized more meticulously how these proteins will 
behave when administered to patients in the scope of clinical trials.  
Besides diagnostic and therapeutic applications, vNAR domains, due to their small size, high stability 
and their ability to sustain repeated cycles of unfolding and folding are also promising biomolecules 
for biotechnological applications to serve for example as high-affinity capturing agents for purification 
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of biomolecules or as tools for diagnostic applications. It was recently shown that vNAR fragments 
can be coupled covalently and site-specifically onto crystalline nanocellulose that serves as a protein-
capturing nanoscaffold.[140] This evidence, coupled with the demonstrated stability and flexibility of 
vNAR domains, would predict more biotechnological applications can be expected to show up in the 
next years. Additionally, the vNAR domain can be utilized to gain information about pathological 
processes that at present are not completely understood. This was exemplified by Nuttall and 
colleagues, who grafted parts of the Aβ-peptide involved in Alzheimer’s disease into CDR3 of a 
vNAR domain and thus solved the crystal structure of the amyloid-β p3 fragment (Fig. 5F).[129]  
 
2.6 Antibody engineering and selection 
Since the development of hybridoma technology in the 1970s by Köhler and Milstein[141], which is 
still state of the art in antibody technology, antibody development and engineering of therapeutic 
antibodies as well as of proteins in general has made continuous progress.[33,142] Nowadays, 
engineering and selection of completely human antibodies is amenable through the generation of 
transgenic animals bearing the genetic information for human antibody repertoires in the absence of 
mouse antibody genes.[143] Favored variants can be selected using the conventional hybridoma 
technology as well as via different display methodologies. Display technologies enable the 
identification of the respective candidates from libraries by the linkage between the protein variant to 
the coding information.[142] Thus, protein engineering and selection is not only limited to antibody 
molecules and it has been shown that an unprecedented range of proteins and enzymes can be 
manipulated as desired.[69,142,144-148]  
In general there are five main display technologies, referred to as phage display, cellular display 
systems, ribosomal display, mRNA display and DNA display.[142] Compared to the other 
aforementioned display systems, cellular screening harbors the advantages of single-cell on-line and 
real-time analysis as well as characterization of individual library members. Moreover, using 
eukaryotic screening platforms, displayed protein variants are believed to be folded correctly, owing to 
the fact that every library member has to pass intrinsic quality control machineries for proper folding 
before getting displayed on the surface of the host cell.[149] Different cellular display platforms, for 
instance bacterial display, yeast surface display and various mammalian display systems have recently 
been reviewed by Kolmar and co-workers.[149] Within these studies, yeast surface display (YSD) was 
used as platform technology and will be scrutinized in more detail.  
Yeast surface display was introduced by Boder and Wittrup in 1997.[150] In this original approach, 
the Aga1p mating adhesion receptor is integrated into the genome of Saccharomyces cerevisiae under 
the control of a galactose-inducible promoter. The gene of interest is cloned as a fusion to the episomal 
encoded AGA2. Both subunits are approximately expressed to the same extent and associate 
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covalently via two disulfide bonds following galactose-induction in the endoplasmatic reticulum. Due 
to a C-terminal glycosylphosphatidylinositol anchor (GPI attachment signal) of Aga1p, the fusion-
construct containing the protein of interest, is displayed on the cell wall in a copy number of 
approximately 10
4
 – 105 respective protein variants (Fig. 7).[149,150] The protein of interest i.e. 
library candidate can be flanked by several epitopes for the detection of surface expression. Besides 
the Aga1p – Aga2p system, various other cell wall proteins have proven to be successful for yeast 
surface display.[151,152] It needs to be mentioned that aside from the platform technology, pioneered 
by Boder and Wittrup, several other display systems are routinely used to engineer proteins, including 
display technologies using Pichia pastoris as host.[149,153,154] Yeast surface display is compatible 
with fluorescence-activated cell sorting (FACS) which enables control over the selection process, i.e. 
the above mentioned on-line and real-time analysis. This allows to fine-tune and to discriminate very 
sensitively for affinity and stability. Another benefit of yeast surface display is the correlation between 
display level on the yeast surface and thermal stability as well as soluble expression level, enabling the 
rapid isolation of stable proteins with desired properties such as affinity.[155] Additionally, affinities 
and stability of individual library candidates can be determined on the yeast surface, which is a 
convenient way to characterize a large number of candidates without the need for soluble 
expression.[146,156] Finally, antibody libraries are suggested to be sampled more comprehensively 
with yeast surface display than with phage display.[157] 
 
Figure 7. Simplified illustration of yeast surface display according to Boder and Wittrup.[150] The protein of interest is 
fused to the C-terminus of Aga2p. Below, the episomal genetic arrangement is shown. Tag: Epitope for the detection of 
surface presentation via immunofluorescence staining. 
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2.7 Target proteins 
In the following section the antigens used in this study are briefly described. Although antigens were 
used as proof-of-concept target proteins, most - if not all - are of therapeutic and/or diagnostic 
relevance.  
 
2.7.1 Epithelial cell adhesion molecule (EpCAM) 
Epithelial cell adhesion molecule EpCAM is expressed on a subset of epithelia where it mediates 
epithelial-specific intercellular cell-adhesion via oligomerization.[158,159] It also plays an important 
role to the formation of tight junctions.[160,161] Though, it was also shown that EpCAM can have a 
negative impact on E-cadherin-mediated cell-cell adhesion, thus promoting cell migration and 
motility.[159,162] EpCAM is overexpressed on malignant cells in a variety of different tumor entities. 
Furthermore, it was identified as a marker for cancer initiating cells.[163,164] In certain tumor types, 
overexpression of EpCAM is correlated with an advanced stage of cancer and with worse overall 
survival as well as risk for recurrence.[158,163] EpCAM is a type I transmembrane glycoprotein and 
consists of a large extracellular domain (EpEX, 27 kDa), a transmembrane domain and a short 
intracellular domain (EpICD).[163] Recently, Lenarcic and co-workers were able to solve the crystal 
structure of EpEX.[159] The group demonstrated that the extracellular domain of EpCAM forms a 
dimer on the cell-surface and provided a model in which intercellular cell-cell contacts are formed 
through EpCAM tetramerization mediated by membrane-distal regions.[159]  
 
2.7.2 Receptor tyrosine kinase EphA2 
Receptor tyrosine kinases are key players in cell signaling pathways in carcinogenesis.[165,166] The 
Eph family, including EphA2, represents the largest group among receptor tyrosine kinases.[167] 
Physiological roles of Eph members include participation in the development of neuronal networks, 
axon guidance, formation and remodeling of synaptic connections and nervous system repair.[168] 
However, EphA2 is overexpressed and functionally altered in a multitude of different cancers, 
including breast cancer, melanomas, ovarian cancer, lung cancer, gliomas, urinary bladder cancer, 
prostate cancer as well as esophageal, renal, colon and vulvar cancers.[167,169,170] Besides being a 
marker for metastatic behavior, it is known that EphA2 overexpression directly promotes an aggressive 
phenotype and its overexpression can induce malignant transformation.[169] Consistently, high EphA2 
expression in tumors is correlated with poor prognosis and recurrence owing to its metastatic 
potential.[167] EphA2 is a large molecule of approximately 130 kDa and consists of an extracellular 
conserved N-terminal ligand binding domain (EphA2 interacts with any of eight different ephrinA-
family ligands [169]), followed by a cysteine-rich domain as well as an EGF-like motif and two 
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fibronectin type III repeats. The extracellular part is followed by a membrane-spanning region and the 
cytoplasmic region that contains a juxtamembrane region, a tyrosine kinase domain, a sterile alpha 
motif and a post synaptic domain.[167]  
 
2.7.3 Interleukin-8 (CXCL8) 
Chemokines are a family of structurally related small proteins (8-10 kDa) involved in the regulation of 
immune processes. CXCL8 is a pro-inflammatory chemokine which acts on leukocytes and endothelial 
cells. Interleukin-8 (IL-8) as well as other pro-inflammatory cytokines have been associated with 
chronic inflammation and inflammatory diseases.[171] IL-8 interacts with receptors CXCR1 and 
CXCR2 with high affinities.[172] Besides its role in inflammation,[173] there is evidence that IL-8 
functions in the tumor microenvironment.[172] The cytokine responds to the activation of NF-κB, 
which is commonly activated in cancer cells. IL-8 is believed to stimulate angiogenesis, cell 
proliferation, survival as well as migration and metastasis.[174] Additionally, the cytokine mediates 
tumor cells to undergo epithelial-mesenchymal transition. Thus, IL-8 and its receptors emerged as 
promising targets for cancer therapy.[172,175] 
 
2.7.4 Cluster of differentiation 3 (CD3) subunit CD3ε 
Cluster of differentiation 3 is a T-cell co-receptor composed of four different chains, CD3γ, CD3δ, 
CD3ζ and CD3ε. The multi-protein complex associates non-covalently with the T-cell receptor, 
representing the T-cell receptor complex.[176] This complex couples antigen-recognition, mediated by 
the variable domains of the T-cell receptor with intracellular signaling and T-cell activation, mainly 
through the ζ-chain.[177] CD3, especially subunit CD3ε is now recognized as a promising target for 
T-cell activation for bi-specific antibodies.[82,178] bsAbs for this kind of immunotherapy bind with 
one arm a tumor-associated antigen, while with the other antigen-binding site the T-cell is engaged 
through CD3ε. Thus, the tumor gets cross-linked to T-cells and the latter are getting simultaneously 
activated for their cytotoxic activity.[178] This cytotoxic activity is owing to the formation of the 
cytolytic synapse i.e. the release of perforin and granzymes by the cytotoxic T-cell and their serial 
target cell lysis capacity.[179,180] To this end, this prospective approach of T-cell engagement already 
reached approval[81] and several molecules are currently assessed in clinical trials.[179] 
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2.7.5 Human Fcγ 
Fcγ is the Fc-part of IgG, the most abundant isotype found in the serum of humans. Due to its long 
serum half-life [31], binding to IgG could significantly increase circulation time of small proteins, such 
as shark vNAR antibody domains. As aforementioned, in a similar approach, executed by Barelle and 
colleagues, binding of a vNAR domain to human serum albumin (HSA) drastically increased the 
serum half-life of this molecule, partially due to HSA recycling, mediated by FcRn.[101]  
 
2.8 Aim of the work 
This work aimed at generating high-affinity antigen binding vNAR molecules from the bamboo shark 
(Chiloscyllium plagiosum) against different disease-related antigens. Thus far, the bamboo shark has 
not been described in literature for the selection of target-specific vNAR molecules. Hence, the main 
objective was to establish a platform for antigen-specific IgNAR V domain generation by resembling 
the natural immune response in sharks using yeast surface display as technology for antibody 
selection.  
For this, binders against the aforementioned target-proteins needed to be selected from a CDR3-
diversified repertoire. Affinity maturation should be demonstrated by the diversification of CDR1 of 
target-enriched antigen binding vNAR populations and sublibrary screening with enhanced stringency, 
to obtain binders with optimized affinities. This strategy kind of mimics the natural mechanism of 
affinity maturation by somatic hypermutation in sharks.     
Additionally, we also set out to generate a new antigen-binding site into the vNAR scaffold that acts 
autonomously from the conventional paratope. Taking a closer look at hypervariable loop 2 (HV2), 
previous studies showed that HV2 is prone to mutations during somatic hypermutation. However, we 
perceived that this loop is located distantly from the conventional paratope, composed of CDR3, 
CDR1 as well as hypervariable loop 4 (Fig. 8). To the best of our knowledge, thus far evidence is 
missing that HV2 ever contributed to antigen binding. Essentially, we attempted to utilize this loop 
(HV2) to generate a new antigen-binding site, resulting in a bi-specific vNAR with the capability to 
address two distinct targets. Ultimately, a bi-specific vNAR molecule would be the smallest bi-specific 
antibody domain known in the animal kingdom. 
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Figure 8. Structure of a vNAR binding domain (left: ribbon model, right: surface) indicating variable regions CDR1, HV2, 
HV4, and CDR3. Disulﬁde bond is shown in yellow. The model was generated on the basis of a published X-ray structure 
(PDB-ID: 1VES) using YASARA structure [107] and rendered with POVRay using radiosity (left) and subsurface light 
transport (right). Figure was constructed in close cooperation with Martin Empting. 
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3. MATERIAL 
3.1 Bacterial strains, yeast strains and cell lines 
Bacterial strains – Escherichia coli 
BMH 71-18 - thi, supE, ∆(lac-proAB), [mutS::Tn10], [F', proAB, laqI q Z∆M15] 
DH5α - F- f80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, mk+) phoAsupE44 thi-1 
gyrA96 relA1 λ- 
TOP 10 - F- mcrA Δ(mrr-hsdRMS-mcrBC) Δ80lacZ ΔM15 ΔlacX74 recA1 araD139 Δ(araleu) 7697 
galU galK rpsL (StrR) endA1 nupG 
 
Yeast strains – Saccharomyces cerevisiae 
EBY100 - a GAL1-AGA1::URA3 ura3-52 trp1 leu2Δ200 his3Δ200 pep4::HIS2 prb11.6R can1 
GAL, Trp-Leu- 
 
Cell lines 
CHO    Chinese hamster ovary 
Cultivation at 37°C, 5 % CO2 
EBC-1   Human lung squamous cell carcinoma 
Cultivation at 37°C, 5 % CO2 
HEK-293   Human embryonic kidney  
Cultivation at 37°C, 5 % CO2 
HT-29    Human colorectal adenocarcinoma  
Cultivation at 37°C, 5 % CO2 
T47D      Human mammary gland, breast tumor  
Cultivation at 37°C, 5 % CO2 
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3.2 Plasmids  
3.2.1 pCT 
 
Figure 9. Vector map for pCT plasmid. Arrows indicate orientations of genetic elements. Trp1: gene sequence for 
phosphoribosyl anthranilate isomerase (auxotrophic marker). AmpR: gene for β-lactamase. Gal1-Promoter: Gal1/10 
promoter region. Aga2p: coding sequence for AGA2 protein. HA-Tag: HA epitope. Gly4Ser3/Linker: glycine-serine linker 
sequence. Trap: partial DNA sequence of TRAP protein (not in frame with Aga2p). cmyc/tag: cMYC epitope coding DNA 
sequence. stop: tandem stop codon. Terminator: terminator sequence.  
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3.2.2 pMX-EETI 
 
 
Figure 10. Vector map for pMX-EETI plasmid. Arrows indicate orientations of genetic elements. LacO: gene sequence for  
lac operon.  Maltose/Bindeprotein: gene for MalE (which is expressed as fusion with protein of interest). EETI: coding 
sequence for EETI protein. stop: stop codon. Acc65I: recognition sequence for restriction enzyme Acc 65I. XbaI: 
recognition sequence for restriction enzyme Xba I. M13 origin: M13 bacteriophage origin of replication. ColE1 origin: 
bacterial origin of replication.  
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3.2.3 pMX-vNAR 
 
Figure 11. Vector map for pMX-vNAR plasmid. Arrows indicate orientations of genetic elements. LacO: gene sequence 
for  lac operon.  Maltose/Bindeprotein: gene for MalE (which is expressed as fusion with protein of interest). Ala-Linker: 
sequence for triple alanine. TEV Site: recognition sequence for tabacco etch virus protease cleavage. vNAR: sequence for 
E. coli codon-optimized vNAR sequence of α-EpCAM-vNAR_5005 stop: stop codon. Acc65I: recognition sequence for 
restriction enzyme Acc 65I. XbaI: recognition sequence for restriction enzyme Xba I. M13 origin: M13 bacteriophage 
origin of replication. ColE1 origin: bacterial origin of replication.  
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3.2.4 pExpress-Fc 
 
Figure 12. Vector map for pExpress-Fc plasmid. Arrows indicate orientations of genetic elements. F1 ori: phage-derived 
origin of replication.  AmpR: gene for β-lactamase. BM40: signal peptide sequence. NheI: recognition sequence for 
restriction enzyme Nhe I. TEV site: : recognition sequence for tabacco etch virus protease cleavage. Hinge: coding 
sequence for hinge region. ApaI: recognition sequence for restriction enzyme Apa I. Fc: coding sequence for domains CH2 
and CH3 of human IgG (non-glycosylated, Asn297 replaced by Ala297). stop: triple stop codon. Promoter sequence of 
cytomegalovirus not shown. 
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3.3 Enzymes, proteins, nucleic acids and protein ladder 
2-Log DNA ladder New England Biolabs (NEB), Beverly, USA 
Acc 65I New England Biolabs (NEB), Beverly, USA 
Anti-CD326 (EpCAM)-PE MACS Miltenyi Biotec, Bergisch-Gladbach, 
Germany 
Anti-cMyc- antibody Made in-house 
Anti-HA-antibody eBioscience, San Diego, USA 
Anti-Hu IgG (Fcγ-specific) PE eBioscience, San Diego, USA 
Αnti-human-Fab-488 conjugate Jackson Immuno Research, Suffolk, UK 
Anti-Mouse IgG Biotin Sigma Aldrich, Steinheim, Germany 
Anti-Mouse IgG FITC Sigma Aldrich, Steinheim, Germany 
Apa I New England Biolabs (NEB), Beverly, USA 
Bam HI GERBU Biotechnik, Heidelberg, Germany 
Bovine serum albumin (BSA) GERBU Biotechnik, Heidelberg, Germany 
dNTPs Carl Roth GmbH, Karlsruhe, Germany 
HTRA1 Made in-house 
Henn egg white lysozyme MP Biomedicals, LCC. Illkirch, France 
(mm) EGFR Merck (EMD) Serono, Darmstadt, Germany 
(mm) EpCAM ACRO Biosystems, Newark, USA 
(mm) EphA2 Sino Biological Inc., Beijing, USA 
Nhe I New England Biolabs (NEB), Beverly, USA 
Oligonucleotide primers Sigma Aldrich, Steinheim, Germany 
Penta-His Alexa Fluor 488 conjugate  Qiagen, Hilden, Germany 
Prestained Protein Marker, Broad Range New England Biolabs (NEB), Beverly, USA 
Reverse transcriptase (Omniscript RT) Qiagen, Hilden, Germany 
(rh)CD3ε ACRO Biosystems, Newark, USA 
(rh) EpCAM ACRO Biosystems, Newark, USA 
(rh) EphA2 R&D Systems, Minneapolis, USA 
(rh) Fcγ (glycosylated) Made in-house 
(rh) Fcγ (non-glycosylated) Made in-house 
(rh) IL-8 Prof. Schmitz, TU Darmstadt, Germany 
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Streptavidin APC (SAPC) eBioscience, San Diego, USA 
Streptavidin-R-phycoerythrin conjugate (SPE) Sigma-Aldrich, Steinheim, Germany 
T4 DNA ligase New England Biolabs (NEB), Beverly, USA 
Taq Polymerase New England Biolabs (NEB), Beverly, USA 
TEV protease  Made in-house 
tGFP Made in-house 
Trypsin-EDTA Gibco(Invitrogen), Karlsruhe, Germany 
Xba I New England Biolabs (NEB), Beverly, USA 
 
3.4 Oligonucleotides 
Name Sequence (5′–3′) 
bamboo/nat_lo  WTTCACAGTCASARKGGTSCC 
bamboo/nat_up  ATGGCCSMACGGSTTGAACAAACACC  
CDR1rand_up ACCATCAATTGCGTCCTAAAA(X)5TTGGGTAGCACGTACTGGTATTTCA
CAAAGAAG 
CDR3rand/Fr4_lo WTTCACAGTCASARKGGTSCCSCCNCCTTCAAT(X)12CGCTTCACAGTGA
TATGTACC 
FR1_up ATGGCCGCACGGCTTGAACAAACACCGACAACGACAACAAAGGAGGC
AGGCGAATCACTGACCATCAATTGCGTCCTAA 
FR1/CDR1/Tyr_up ACCATCAATTGCGTCCTAAAAGGTTCCRNMTATGBATTGGGTANMACG
TACTGGT 
FR3_lo CGCTTCACAGTGATATGTACC 
GR_up GTGGTGGTGGTTCTGCTAGCATGGCCGCACGGCTTGAACA 
GR_lo ATAAGCTTTTGTTCGGATCCWTTCACAGTCASARKGGTSCCSCCNCC 
HV2_B1mut_lo TGTGTCCGAGTAGCGTCCGCCCATCCATTT 
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HV2_B1mut_up AAATGGATGGGCGGACGCTACTCGGACACA 
 
HV2_SOE_lo GCCCTTCTTTGTGAAATACCA 
HV2_SOE_rand_up TGGTATTTCACAAAGAAGGGC(X)9GCGGACGATACTCGGACACA 
pCT_Seq_lo GCGCGCTAACGGAACGAAAAATAGAAA 
pCT_Seq_up GCGGCGGTTCCAGACTACGCTCTGCAGGCT 
pEXPR_vNARB1mut_loI GGGTCTTGTCGCAGCTCTTGGGCTCGCTTCCGCTCTGGAAGTACAGGTT
CTCTTTCACAGTCACAGTGGTC 
pEXPR_vNARB1mut_loII GAACACGCTGGGCCCGCCCAGCAGTTCAGGGGCAGGGCAGGGAGGAC
AGGTGTGGGTCTTGTCGCAGCTCT 
pEXPR_vNAR_loI GCAGGGAGGACAGGTGTGGGTCTTGTCGCAGCTCTTGGGCTCGCTTCC
ATTCACAGTCACAAGGGTCCC 
pEXPR_vNAR_loII GGAACACGCTGGGCCCGCCCAGCAGTTCAGGGGCAGGGCAGGGAGGA
CAGGTGTGGGTCTTGTCGCA 
pEXPR_vNAR_up TGGCCGGAAGGGCGCTAGCCGCTGAGAACCTGTACTTCCAGAGCATGG
CCGCACGGCTTGAACA 
 
pMX_vNAR_lo TCGACCTCTAGAGCGGCCGCTTAATGATGATGATGATGATGCGCCGCC
GCATTCACAGTCACAAGGGTCCC 
pMX_vNAR_up AATTCGAGCTCGGTACCCGCGGCGGCGGAAAACCTGTATTTTCAGAGC
ATGGCCGCACGGCTTGAACAA 
X: triplet codon for all natural amino acids w/o Cys; B: G/C/T; K: G/T; M: A/C; N: A/G/C/T; 
R: A/G; S: G/C; W: A/T. 
 
3.5 Chemicals 
2-Mercaptoethanol  Carl Roth GmbH, Karlsruhe, Germany 
Acetic Acid Carl Roth GmbH, Karlsruhe, Germany 
Acrylamide/Bisacrylamide (37,5:1) Carl Roth GmbH, Karlsruhe, Germany 
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Agar-Agar Carl Roth GmbH, Karlsruhe, Germany 
Agarose Ultra-Quality Carl Roth GmbH, Karlsruhe, Germany 
Ammonium acetate Carl Roth GmbH, Karlsruhe, Germany 
Ammonium hydrogene carbonate Carl Roth GmbH, Karlsruhe, Germany 
Ampicillin, sodiumsalt Carl Roth GmbH, Karlsruhe, Germany 
APS Carl Roth GmbH, Karlsruhe, Germany 
Bacillol plus Carl Roth GmbH, Karlsruhe, Germany 
Bromophenol blue Carl Roth GmbH, Karlsruhe, Germany 
Calcium chloride Carl Roth GmbH, Karlsruhe, Germany 
Casaminoacids  Becton Dickinson GmbH, Heidelberg, Germany 
Citric acid Carl Roth GmbH, Karlsruhe, Germany 
Chloramphenicol Carl Roth GmbH, Karlsruhe, Germany 
Chloroform Fisher Scientific, Schwerte, Germany 
Coomassie brilliant blue R250 Carl Roth GmbH, Karlsruhe, Germany 
Di-sodium hydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany 
Dithiothreitol  Carl Roth GmbH, Karlsruhe, Germany 
DMSO Sigma Aldrich, Steinheim, Germany 
Ethanol Carl Roth GmbH, Karlsruhe, Germany 
EDTA Applichem GmbH, Darmstadt, Germany 
Ethidium bromide Carl Roth GmbH, Karlsruhe, Germany 
Fetal bovine serum Sigma-Aldrich, Steinheim, Germany 
Galactose Sigma-Aldrich, Steinheim, Germany 
Gel loading dye (6x) New England Biolabs (NEB), Beverly, USA 
Glucose Carl Roth GmbH, Karlsruhe, Germany 
Glycerol  Carl Roth GmbH, Karlsruhe, Germany 
Glycerin Carl Roth GmbH, Karlsruhe, Germany 
HCl Carl Roth GmbH, Karlsruhe, Germany 
HDgreen Plus DNA Stain INTAS, Göttingen, Germany 
Imidazole  Carl Roth GmbH, Karlsruhe, Germany 
Isopropyl alcohol Carl Roth GmbH, Karlsruhe, Germany 
IPTG Carl Roth GmbH, Karlsruhe, Germany 
Lithium acetate Carl Roth GmbH, Karlsruhe, Germany 
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L-Glutamine Sigma Aldrich, Steinheim, Germany 
Magnesium chloride Carl Roth GmbH, Karlsruhe, Germany 
Methanol  Carl Roth GmbH, Karlsruhe, Germany 
Nickel chloride Merck KGaA, Darmstadt, Germany 
Paraffin oil Carl Roth GmbH, Karlsruhe, Germany 
Penicillin/Streptomycin (100x) Life Technologies, Darmstadt, Germany 
Phenol Carl Roth GmbH, Karlsruhe, Germany 
Peptone/Tryptone Carl Roth GmbH, Karlsruhe, Germany 
Polyethylene glycol 8000  Carl Roth GmbH, Karlsruhe, Germany 
Potassium chloride Carl Roth GmbH, Karlsruhe, Germany 
Potassium di-hydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany 
Potassium hydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany 
Potassium hydroxide  Carl Roth GmbH, Karlsruhe, Germany 
Sucrose Carl Roth GmbH, Karlsruhe, Germany 
SDS, ultra pure Carl Roth GmbH, Karlsruhe, Germany 
Sodium chloride Carl Roth GmbH, Karlsruhe, Germany 
Sodium hydroxide Carl Roth GmbH, Karlsruhe, Germany 
Sodium di-hydrogen phosphate di-hydrate Carl Roth GmbH, Karlsruhe, Germany 
Sorbitol  Carl Roth GmbH, Karlsruhe, Germany 
Sulfo-NHS-LC-Biotin  Thermo Fisher Scientific, Geel, Belgium 
Sypro Orange Gel Protein Stain Sigma Aldrich, Steinheim, Germany 
TEMED Merck KGaA, Darmstadt, Germany 
TRIS Carl Roth GmbH, Karlsruhe, Germany 
Tri-sodium citrate Carl Roth GmbH, Karlsruhe, Germany 
Yeast extract Carl Roth GmbH, Karlsruhe, Germany 
Yeast Nitrogen Base Becton Dickinson GmbH, Heidelberg, Germany 
TWEEN-20 Carl Roth GmbH, Karlsruhe, Germany 
Triton X-100 Carl Roth GmbH, Karlsruhe, Germany 
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3.6 Solutions and buffers 
1x SDS running buffer  Tris 50 mM, Glycin 190 mM, SDS 1 g/l 
4x PAGE buffer A  Tris/HCl 3 M (pH 8.85), SDS 4 g/l  
4x PAGE buffer B Tris/HCl 0.5 M (pH 6.8), SDS 4 g/l  
5x PAGE loading buffer  Tris/HCl 0.25 M (pH 8), SDS (7.5 % (w/v), 
Glycerin 25 % (w/v), bromphenol blue 
0.25 mg/ml, 2-mercaptoethanol 12.5 % (w/v) 
APS-stock 10 % (w/v) 
Coomassie staining solution Acetic acid 10 % (v/v), methanol 40 % (v/v), 
Coomassie brilliant blue R250 0.25% (w/v) 
Electroporation buffer (yeast) Sorbitol 1 M, calcium chloride 1 mM 
IMAC EDTA solution EDTA 100 mM 
IMAC elution buffer Imidazol 1M in PBS (pH 7.4) 
IPTG stock IPTG 1 M 
Kinetics buffer (FortéBio) PBS (pH 7.4), 0.1 % BSA (w/v), 0.02 % 
Tween-20 
LiAc/DTT buffer Lithium acetate 100 mM, Dithiothreitol 10 mM 
Nickel chloride solution Nickel chloride 100 mM 
Periplasm buffer Sucrose 0.5 M, Tris/HCl 0.1 M, EDTA 1 mM 
Phosphate-buffered saline (PBS) 8.1 g/L NaCl, 0.75 g/L KCl, 1.13 g/L Na2HPO4 
and 0.27 g/L KH2PO4, pH 7.4 
Protein A chromatography running buffer Sodium di-hydrogen phosphate di-hydrate 
1.08 g/L, Di-sodium hydrogen phosphate 
1.72 g/L (pH 7.0) 
Protein A chromatography elution buffer Citric acid 17.2 g/L, Tri-sodium citrate 5.28 g/L 
(pH 3.0) 
Protein A chromatography collection buffer Tris/HCl 1 M (pH 9.0) 
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TAE buffer (50x) Tris 2 M, acetic acid 1M, EDTA 0.1 M  
TE buffer Tris/HCl 10 mM (pH 8.0) 
TEV protease reaction buffer (10x) 500 mM Tris/HCl (pH 7.5), 1.5 M NaCl 
Trypan blue solution Trypan blue 4 % (w/v) 
Yeast freezing solution Glycerol 2 % (v/v), yeast nitrogen base 0.67 % 
(w/v) 
Yeast lysis buffer Tris/HCl 10 mM (pH 8), NaCl 100 mM, SDS 1 % 
(w/v), EDTA 1 mM, Triton X-100 2 % (v/v) 
 
3.7 Cell culture media 
E. coli 
dYT  Yeast extract 10 g/L, peptone/tryptone 16 g/L, 
NaCl 5 g/L  
 
S. cerevisiae 
SD-CAA  Yeast nitrogen base without amino acids and 
ammonium sulfate 1.7 g/L, ammonium sulfate 
5 g/L, 5 g/L casamino acids, 20 g/L dextrose, 
8.6 g/L NaH2PO4 × H2O, 5.4 g/L Na2HPO4  
SG-CAA Yeast nitrogen base without amino acids and 
ammonium sulfate 1.7 g/L, ammonium sulfate 
5 g/L, 5 g/L casamino acids, 20 g/L galactose, 
8.6 g/L NaH2PO4 × H2O, 5.4 g/L Na2HPO4, 
polyethylene glycol 8000 10 % (w/v) 
YPD 20 g/L tryptone, 20 g/L dextrose and 10 g/L yeast 
extract 
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human cell line HEK293 
Freestyle™ 293 expression medium Life Technologies, Darmstadt, Germany 
 
3.8 Laboratory materials and kits 
5 ml tubes for FACS Saarstedt, Nümbrecht, Germany 
50 ml centrifuge tubes with screw caps Carl Roth GmbH, Karlsruhe, Germany 
emPCR Kit (Lib-A) 454 Life Sciences (Roche), Branford, USA 
Expi293™ Expression System Kit Life Technologies, Darmstadt, Germany 
Filtropure filter devices Saarstedt, Nümbrecht, Germany 
FortéBio tips FortéBio, Menlo Park, California, USA 
GS Junior Titanium PicoTiterPlate Kit 454 Life Sciences (Roche), Branford, USA 
GS Junior Titanium Sequencing Kit 454 Life Sciences (Roche), Branford, USA 
Dialysis membranes Carl Roth GmbH, Karlsruhe, Germany 
MicroBeads Beckman Coulter GmbH, Krefeld, Germany 
Mikrotiter plates 96-well (for FortéBio) Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Omniscript® Reverse Transcription Kit Qiagen, Hilden, Germany 
Protein Desalting Spin Columns Thermo Scientific, Rockford, USA 
Protein purification columns, miscellaneous GE Healthcare Europe GmbH, Freiburg, 
Germany 
Sphero™ rainbow calibration particles Spherotech Inc, Lake Forest, USA 
Tri
®
 Reagent BD Sigma Aldrich, Steinheim, Germany 
Wizard® Plus SV Midipreps DNA Purification 
System 
Promega, Mannheim, Germany 
Wizard® Plus SV Minipreps DNA Purification Promega, Mannheim, Germany 
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System 
Wizard® SV Gel and PCR Clean-Up System  Promega, Mannheim, Germany 
Further materials comprised common laboratory devices. 
 
3.9 Equipment 
Äkta Basic UV900 P900 Frac 900, Unicorn 3.1 
Software 
GE Healthcare Europe GmbH, Freiburg, 
Germany 
BioRad 96CFX RT-PCR detection system Bio-Rad, München, Germany 
Fluorescence Activated Cell Sorter (FACS), 
MoFlo® Cytometer with Cyclone sorting unit, 
Summit® v4.3 Software package 
Dako Cytomation, Fort Collins, USA 
 
FortéBio octet red FortéBio, Menlo Park, California, USA 
Gel documentation system, Gel Jet Imager INTAS Science Imaging Instruments GmbH, 
Göttingen 
Gene Pulser® und pulse controller BioRad, München 
GS Junior System (454 Sequencing) 454 Life Sciences (Roche), Branford, USA 
Microscope Axioskop  Carl Zeiss Microscopy GmbH, Jena, Germany 
PCR Cycler Eppendorf Mastercycler Eppendorf, Hamburg, Germany 
Further equipment comprised common laboratory instrumentation. 
 
3.10 Animals 
Three specimen of the bamboo shark (Chiloscyllium plagiosum) in the age of approximately eight 
months were obtained from the Vivarium of the Staatliches Museum für Naturkunde, Karlsruhe, 
Germany. Procedures were conducted in accordance with the national laws § 4 Abs. 3 of the German 
Tierschutzgesetz (TierSchG, animal welfare act). Permission number: V 54 – 19 c 20 15 (1) Gl 18/19 
Nr. A 35/2011, Regierungspräsidium Giessen, Germany (Regional council Giessen). 
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4. METHODS 
4.1 Analysis of the natural repertoire of the bamboo shark 
Blood samples of one individual of the bamboo shark (C. plagiosum) were harvested from the caudal 
vein and subsequently transferred into Tri
®
 Reagent BD (Sigma Aldrich). Total RNA was extracted 
from whole blood according to the manufacturer’s protocol (Sigma Aldrich). The Omniscript® 
Reverse Transcription Kit (Qiagen) was used for cDNA synthesis as described in the manufacturer’s 
protocol. Five reactions of pooled total RNA from one individual were carried out in parallel, each 
containing about 2 µg of total RNA as template using an oligo(dT)18 primer. From each reaction 5 µl 
were used for the follow-up gene-specific amplification of the vNAR domain using the primers 
bamboo/nat_up and bamboo/nat_lo (3.4). Polymerase chain reaction (PCR) conditions were as 
follows: 94 °C for 2 min, 30 cycles of 30 s at 94 °C, 30 s at 55 °C and 40 s at 72 °C, followed by 72 °C 
for 7 min. PCR products were pooled, purified via the Wizard® SV Gel and PCR Clean-Up System 
(Promega) and the vNAR repertoire was analyzed using next-generation sequencing on 454 GS Junior 
System platforms (Roche) according to the manufacturer’s instructions. In general, in a first PCR 
multiplex identifier sequences (MID sequences) were fused to the PCR product for the identification 
and assignment of vNAR sequences. In a subsequent emulsion PCR (emPCR Kit (Lib-A)) single DNA 
fragments were immobilized on beads via specific oligonucleotides and amplified in “micro-reactor” 
emulsion droplets achieving clonality. After loading of the beads onto a pico-titer plate device the 
sequencing reaction was performed. Data was analyzed using the GS Junior System software package 
v2.7, Jemboss (v1.5), jalview(v2) and muscle(v3.8.31). Deep sequencing was performed in 
cooperation with Andreas Christmann and Janine Becker (Technische Universität Darmstadt).  
To gather information about the established vNAR library (4.2.1), the amino acid distribution of CDR3 
was assessed via deep-sequencing. Evaluation was conducted akin to the analysis of the natural 
repertoire of the bamboo shark. However, in contrast to this, plasmid DNA of the vNAR library was 
isolated (4.2.2) and amplified using primer pair GR_up/GR_lo. PCR conditions were as follows: 94 °C 
for 2 min, 30 cycles of 30 s at 94 °C, 30 s at 55 °C and 40 s at 72 °C, followed by 72 °C for 7 min. 
PCR products were purified via the Wizard® SV Gel and PCR Clean-Up System (Promega) and the 
vNAR repertoire was analyzed using next-generation sequencing on 454 GS Junior System platforms 
(Roche) according to the manufacturer’s instructions. 
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4.2 Yeast surface display library construction and establishment of randomized 
sublibraries for affinity maturation 
4.2.1 CDR3-randomized library construction  
Blood samples of three individuals of the bamboo shark (C. plagiosum) were harvested from the 
caudal vein and subsequently transferred into Tri
®
 Reagent BD (Sigma Aldrich). Total RNA from 
three individuals were used as template for cDNA synthesis using the Omniscript® Reverse 
Transcription Kit (Qiagen) and OdT-Oligonucleotides. From each individual three reactions were 
processed in parallel, each containing approximately 2 µg of RNA. From each reaction 5 µl were used 
for the follow-up gene-specific amplification as mentioned above. PCR products were pooled and 
purified using the Wizard® SV Gel and PCR Clean-Up System (Promega) according to the 
manufacturer’s protocol. The PCR amplified vNAR products were used as starting material for the 
semi-synthetic library construction.  
The initial library was established in three consecutive PCR-steps (Fig. 14). For all reactions the 
conditions were: 94 °C for 2 min, 35 cycles of 30 s at 94 °C, 30 s at 55 °C and 40 s at 72 °C, followed 
by 72 °C for 7 min. Primer sequences are listed in section 3.4. In the first reaction PCR amplified 
vNAR product from the natural repertoire was used as template with the primer combinations 
FR1/CDR1/Tyr_up and FR3_lo. The forward primer replaced Cys by Tyr and incorporated a marginal 
diversity within CDR1. The PCR product was purified via Wizard® SV Gel and PCR Clean-up 
System (Promega). Subsequently, the second PCR was performed to fully randomize CDR3 using the 
primer-combination FR1_up and CDR3/rand/FR4_lo. After purification by Wizard® SV Gel and PCR 
Clean-up System, the PCR product was used as a template for the third reaction using primers with 
overlaps up- and downstream of the Nhe I and Bam HI restriction sites of the pCT-plasmid, 
respectively (GR_up and GR_lo) and purified by Wizard® SV Gel and PCR Clean-up System.  
The pCT vector (3.2.1) was digested with Nhe I and Bam HI. The reaction was performed in a volume 
of 100 µl. For this, approximately 20 µg plasmid were used as well as 100 U restriction enzyme, 
respectively, and incubated overnight at 37 °C. The reaction mixture was purified via Wizard® SV Gel 
and PCR Clean-up System.  
Library was established via an improved yeast transformation method according to Benatuil et al. in a 
homologous recombination-based process referred to as plasmid gap repair.[181] For electroporation 
1-2 µg of the digested plasmid and 6-8 µg of insert were used. Settings on the Gene Pulser® were as 
followed: 2.5 kV and 25 µF. Time constants ranged from 3.0 to 4.5 ms. Library size was calculated by 
dilution plating after 2 days. Yeast cells (EBY 100) were transferred into SD-CAA medium. Stocks 
were stored at -80 °C in yeast freezing solution. For yeast surface display cells were grown overnight 
at 30 °C in SD-CAA medium, transferred into SG-CAA medium and incubated for 1-2 days at 20 °C.  
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4.2.2 Establishment of randomized sublibraries for affinity maturation 
For affinity maturation of the particular enriched antigen binding population, plasmid-DNA was 
isolated from yeast cells after sorting the cells via FACS and incubation at 30 °C for two days. To this 
end, 2 ml of yeast cell suspension were centrifuged (16100 g, room temperature, 1 min) and 
resuspended in 200 µl yeast lysis buffer. Chloroform and phenol were added in a volume of 100 µl, 
respectively, and cells were incubated at room temperature and 1000 rpm for approximately 10 min. 
After centrifugation (16100 g, 4 °C, 15 min) the supernatant was used as template for library 
establishment in a volume of 3 µl per PCR.   
Sublibraries with totally randomized CDR1 were constructed in a 3-step PCR with the following 
conditions: 94 °C for 2 min, 35 cycles of 30 s at 94 °C, 30 s at 55 °C and 40 s at 72 °C, followed by 
72 °C for 7 min. Akin to randomization of CDR3, in the first PCR reaction, the primer pair 
CDR1rand_up/GR_lo was used to randomize CDR1 followed by two consecutive PCR reactions with 
primer pairs FR1_up/GR_lo and GR_up/GR_lo, respectively. After each reaction step, the PCR 
product was purified via Wizard® SV Gel and PCR Clean-up System. Gap repair cloning and 
transformations were executed as described above (4.2.1). 
 
4.2.3 Construction of a HV2-diversified library for the isolation of bi-specific IgNAR V 
domains 
For the construction of a HV2-randomized yeast surface display library based on EpCAM-binding, 
affinity optimized single clone α-EpCAM-vNAR 5005, total DNA was isolated and used as starting 
material. For this, 2 ml of yeast cell suspension were centrifuged and plasmid DNA was isolated as 
aforementioned (4.2.3). 
This particular library was established in a consecutive two-step splicing by overlap extension PCR. 
For the first PCR step, two reactions were carried out in parallel, each containing 3 µl isolated plasmid 
DNA as template. In one reaction, primer pair HV2_SOE_rand_up/pCT_Seq_lo was used. In the other 
reaction, primer pair pCT_Seq_up/HV2_SOE_lo was used. PCR conditions were as followed: 94 °C 
for 2 min, 35 cycles of 30 s at 94 °C, 30 s at 55 °C and 40 s at 72 °C, followed by 72 °C for 7 min. The 
respective PCR products were purified using Wizard® SV Gel and PCR Clean-up System. For the 
subsequent PCR, 1 µl of PCR product was used as template, respectively. After 6 cycles, primer pair 
pCT_Seq_up/pCT_Seq_lo was added. The resulting PCR product was purified via Wizard® SV Gel 
and PCR Clean-up System. Gap repair cloning and transformations were executed as described above. 
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4.3 Binding assays on the yeast surface and library screening for the isolation of 
target-specific vNAR molecules 
4.3.1 Library analysis using yeast surface display 
Flow cytometry was used to analyze presentation on the yeast surface and for single clone analysis. 
About 10
7
 cells were labeled consecutively with anti-cMyc antibody (monoclonal, mouse, made in-
house) or with anti-HA-tag antibody (polyclonal, rabbit, eBioscience, diluted 1:10), anti-mouse IgG 
biotin conjugate (goat, Sigma Aldrich, diluted 1:10 in PBS) or anti-rabbit-biotin (goat, Sigma Aldrich) 
and streptavidin-allophycocyanin conjugate (eBioscience, diluted 1:10) for at least 10 min on ice.  
 
4.3.2 Single clone analysis using yeast surface display 
For single clone analysis, vNAR-presenting cells were either incubated with biotinylated or His-tagged 
antigen for 15 min on ice and subsequently stained with Steptavidin-APC (diluted 1:10) or Penta-His 
Alexa Fluor 488 conjugate (Qiagen, diluted 1:30) for 10 min. When biotinylated antigen was used, 
analysis of surface presentation was conducted using anti-cMyc antibody and anti-mouse FITC 
conjugate (goat, Sigma Aldrich, diluted 1:10).  
For biotinylation of target proteins, Sulfo-NHS-LC-Biotin (Thermo Fisher Scientific) was used as 
reagent. For this, a 20-fold molar excess of biotin reagent was used. All reactions were carried out in 
PBS for 2 hours on ice. To remove non-reacted biotin reagent, biotinylated protein was purified using 
protein desalting sping columns (Thermo Fisher Scientific) according to the manufacturer’s 
instructions for buffer exchange. 
Plasmid DNA from FACS-positive clones was isolated as aforementioned (4.2.2) and PCR product, 
established in a PCR using primer pair pCT-seq_up/pCT_seq_lo, was sent out for sequencing with 
either pCT-seq_up or pCT-seq_lo. 
 
4.3.3 Affinity titration on the yeast surface for the calculation of the equilibrium 
dissociation constant 
Affinities of isolated vNAR variants on yeast cells were determined as described [156,182]. Flow 
cytometric analysis was performed to determine cMyc normalized antigen binding. Hence, exclusively 
cells displaying the vNAR domain were included for KD calculation. Therefore, yeast cells 
(approximately 10
6
 cells for each antigen-concentration) were labeled with anti-cMyc antibody for at 
least 15 min. Afterwards, cells were washed using PBS and resuspended in the respective 
concentration of antigen as well as anti-mouse IgG biotin conjugate was added. When biotinylated 
antigen was used for affinity calculation, anti-mouse FITC conjugate was employed. Cells were 
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incubated for approximately 1 hour with the respective antigen-concentration. After washing, detection 
reagents were added for about 10 min, followed by an additional washing step (Penta-His Alexa Fluor 
488 conjugate, Steptavidin-APC or Anti-Hu IgG (Fcγ-specific) PE for detection of antigen binding as 
well as anti-mouse FITC or Steptavidin-APC for the detection of surface presentation). In general, at 
least eight different antigen concentrations were used. For the final calculation, cMyc-normalized RFU 
were plotted against antigen concentration. EC50 was determined using equation 
y = ymin+(ymax*x/(x+KD)).  
 
4.3.4 Library screening using yeast surface display 
Library screening for the isolation of antigen-specific vNAR molecules was performed on a 
fluorescence activated cell sorter (FACS) MoFlo® Cytometer with Cyclone sorting unit and analyzed 
via Summit® v4.3. For two-dimensional screening, cells were first labeled for detection of surface 
presentation via cMyc labeling. After washing with ice-cold PBS, cells were resuspended in PBS 
containing the desired concentration of antigen and incubated on ice for at least 30 min. Subsequently, 
antigen binding was detected using streptavidin-allophycocyanin conjugate, Anti-Hu IgG (Fcγ-
specific) PE or Penta-His Alexa Fluor 488 conjugate (diluted 1:10, 1:30 or 1:30, respectively, 10 min 
on ice). For the first rounds of sorting of the initial library, approximately 2 x 10
8
 cells were analyzed 
and sorted. Consecutive rounds were performed with at least a 10-fold excess of cells that were 
collected in the previous round to ensure coverage of the enriched population. Sublibrary screening 
was executed with at least 10-fold the number of cells of the theoretical library diversity. 
 
4.4 Soluble expression of vNAR constructs in E. coli and protein purification 
4.4.1 Cloning of vNAR fragments  
Selected vNARs were expressed in the pMX vector [183] that introduces maltose binding protein 
(MalE) and a hexahistine tag for fusion protein expression and purification (Fig. 26).  
pMX vector, containing for E.coli codon-optimized α-EpCAM-vNAR DNA-sequences for variant 
5005 was purchased at GeneArt (Life Technologies). Codon-optimization was performed according 
the manufacturer’s software. For expression of α-EpCAM-vNAR variants H3 and H5, total DNA was 
isolated from the respective single clones (4.2.2). IgNAR V domain fragments were amplified in a 
PCR reaction using primer combination pMX_vNAR_up/pMX_vNAR_lo and 3 µl isolated total DNA 
as template. PCR conditions were as followed: 94 °C for 2 min, 35 cycles of 30 s at 94 °C, 30 s at 
55 °C and 40 s at 72 °C, followed by 72 °C for 7 min. PCR products were purified using Wizard® SV 
Gel and PCR Clean-up System.  
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Afterwards, PCR-products as well as pMX-vector (3.2.2) were digested using Acc 65I and Xba I. PCR 
products as well as pMX plasmid were digested in a volume of 50 µl, respectively. For this, 40 µl PCR 
product or pMX plasmid was used as well as 50 U restriction enzymes, respectively. Digestion was 
performed over night at 37 °C. Digested PCR products were purified via Wizard® SV Gel and PCR 
Clean-up System. Digested pMX plasmid was gel-purified (1 % w/v Agarose) also using the Wizard® 
SV Gel and PCR Clean-up System according to the manufacturer’s protocol.  
Subsequently digested vNAR DNA fragments were ligated into the pMX vector. For this purpose, 
10 µl plasmid (corresponding to approximately 100 ng gel-purified plasmid) and 10 µl digested vNAR 
DNA (about 400 ng) were utilized. Reaction was performed in a volume of 30 µl with 400 U T4 DNA 
ligase added, for 2 hours at room temperature. After this, reaction mixture was purified using the 
Wizard® SV Gel and PCR Clean-up System.  
Electro-competent E. coli TOP 10 cells (100 µl) were transformed with 15 µl purified ligation mixture. 
Settings on the Gene Pulser® were as followed: 2.5 kV and 25 µF. Time constants varied between 4.5 
and 5.0 ms. For the generation of electro-competent TOP 10 cells, E. coli cells were grown to an OD600 
of approximately 0.7 in a volume of 50 ml and washed thrice with ice-cold deionized water (50 ml, 
30 ml, 20 ml). Cells were resuspended in the residual supernatant and used for transformation. Plasmid 
DNA of transformed TOP 10 cells was isolated using Wizard® Plus SV Minipreps DNA Purification 
System (Promega) according to the manufacturer’s instructions and sent out for sequencing.   
 
4.4.2 Soluble expression and purification 
Electro-competent E.coli BMH 71-18 cells were generated akin to the protocol for electro-competent 
E.coli TOP 10 cells (4.4.1) and transformed with plasmids pMX_αEpCAM-vNAR_H3, 
pMX_αEpCAM-vNAR_H5 and pMX_αEpCAM-vNAR_5005, respectively. Cells containing the 
respective plasmid were grown to an OD600 between 0.7 and 1 in dYT medium (1 L) containing 
25 mg/L chloramphenicol and protein production was induced with 1 mM IPTG. Cells were grown 
overnight (approx. 16 h) at 29 °C and harvested by centrifugation.  
For the isolation of the periplasmic fraction, cells were resuspended in approximately 40 ml ice-cold 
periplasm buffer. 40 µl of a lysozyme stock (100 mg/ml in periplasm buffer) were added and incubated 
on a tumbling shaker for 30 min on ice. After centrifugation (16000 g, 15 min, 4 °C) the supernatant 
was harvested. 
Respective recombinant vNAR proteins were purified by metal chelate affinity chromatography 
(HisTrap, GE Healthcare), equilibrated in PBS, pH 7.4. Protein was eluted using a linear imidazole 
gradient (0 % - 100 % of IMAC elution buffer over 30 min) and dialyzed overnight in 5 L PBS at 8 °C 
(ZelluTrans, Carl Roth GmbH, MWCO 3500).  
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For tabacco etch virus protease (TEV) cleavage, 10-fold TEV buffer (1.5 M NaCl, 500 mM Tris-HCl, 
pH 7.5) and recombinant TEV protease (ratio 1:20) were added and incubated overnight at 4 °C.  
Final purification was performed using gel filtration on either a Superdex 200 pg 16/60 or on a 
Superdex 75 pg 16/60 (GE Healthcare), equilibrated with PBS, pH 7.4.  
Proteins were analyzed via SDS-PAGE (15 % v/v SDS gels). For this, 5x PAGE loading buffer was 
added to protein samples. After electrophoresis, gel was stained using coomassie staining solution.   
 
4.5 Soluble expression of formatted vNAR-Fc fusion constructs in mammalian cells 
and protein purification 
4.5.1 Formatting of vNAR fragments  
EpCAM-binding, affinity-optimized vNAR 5005 as well as its bi-specific progeny, EpCAM- and 
CD3ε-binding vNAR B1mut were expressed in mammalian cells. Therefore, both IgNAR V domains 
were cloned into pExpress vector that introduces the human Fc-part (3.2.4).  
For this, total DNA was isolated from single clones, respectively (4.2.2). IgNAR V domain DNA 
fragment for mono-specific variant 5005 was amplified in a consecutive 2-step PCR containing primer 
pairs pEXPR_vNAR_up/pEXPR_vNAR_loI and pEXPR_vNAR_up/pEXPR_vNAR_loII, 
respectively. PCR conditions were as followed: 94 °C for 2 min, 35 cycles of 30 s at 94 °C, 30 s at 
55 °C and 40 s at 72 °C, followed by at 72 °C for 7 min. First PCR was executed using 3 µl isolated 
total DNA. PCR product was purified PCR using Wizard® SV Gel and PCR Clean-up System. 1 µl 
PCR product was used as template for the second reaction.  
Akin to this, vNAR DNA fragment for bi-specific variant B1mut was amplified under same 
conditions. However, primer pairs pEXPR_vNAR_up/pEXPR_B1mut_loI and 
pEXPR_vNAR_up/pEXPR_B1mut_loII were utilized.  
Afterwards, PCR-product as well as pExpress-Fc plasmid (3.2.4) were digested using Apa I and Nhe I. 
PCR products as well as pExpress-Fc plasmid were digested in a volume of 50 µl, respectively. For 
this, 40 µl PCR product or pMX plasmid were at first incubated with 50 U Apa I at 25 °C for 3 hours. 
Then 50 U Nhe I were added and reaction mixture was incubated overnight at 37 °C. Digested 
products were purified via Wizard® SV Gel and PCR Clean-up System.  
Subsequently digested vNAR DNA fragments were ligated into the pExpress-Fc vector. For this 
purpose, 5 µl plasmid (corresponding to approximately 300 ng plasmid) and 10 µl digested vNAR 
DNA (about 500 ng) were used. Reaction was performed in a volume of 30 µl with 400 U T4 DNA 
ligase added, for 2 hours at room temperature. After this, reaction mixture was purified using the 
Wizard® SV Gel and PCR Clean-up System.  
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Electro-competent E. coli TOP 10 cells (100 µl) were transformed with 15 µl purified ligation mixture. 
Settings on the Gene Pulser® were as followed: 2.5 kV and 25 µF. Time constants varied between 4.5 
and 5.0 ms. Plasmid DNA of transformed E. coli TOP 10 cells was isolated using Wizard® Plus SV 
Minipreps DNA Purification System and sent out for sequencing. For transfection of mammalian cells, 
large amounts of plasmid DNA were generated and isolated using the Wizard® Plus SV Midipreps 
DNA Purification System (Promega) after the manufacturer’s instructions. 
 
4.5.2 Soluble expression of vNAR-Fc fusion proteins using the Expi293™ Expression 
System Kit 
Expi293™ cells were cultured at 37 °C, 5 % CO2 and 100 rpm in Expi293™ expression medium. 
Transfection was performed in a 30 ml scale. For this, 2.9 x 10
6
 viable cells/ml were seeded in 
approximately 25 ml of Expi293™ expression medium. 30 µg plasmid DNA 
(pExpress_αEpCAM-vNAR_5005) were added to Opti-MEM® I reduced serum medium to a total 
volume of 1.5 ml. 81 µl of ExpiFectamine™ 293 were diluted in Opti-MEM® I reduced serum 
medium to a volume of 1.5 ml. After 5 min incubation, Opti-MEM® I reduced serum medium 
containing the DNA was added to the ExpiFectamine™ 293/Opti-MEM® I reduced serum medium 
mixture. After 20 min incubation at room temperature, transfection mixture was added to the cells. 
After one day incubation (37 °C, 5 % CO2 and 100 rpm), 150 µl ExpiFectamine™ 293 transfection 
enhancer 1 and 1.5 ml  ExpiFectamine™ 293 transfection enhancer 2 were added. Cells were 
incubated for 4 more days and supernatant was harvested by centrifugation (4500 g, 10 min, 4 °C). 
Soluble expression with Expi293™ cells was carried out at Merck KGaA (Darmstadt).  
 
4.5.3 Soluble expression of vNAR-Fc fusion in HEK293 cells and purification  
HEK293 cells were cultured at 37 °C, 5 % CO2 and 100 rpm in Freestyle™ 293 expression medium. 
One day post transfection approximately 1 x 10
6
 viable cells/ml were seeded in 25 ml Freestyle™ 293 
expression medium. On the day of transfection, cells were typically grown to 1.7 – 1.9 x 106 viable 
cells/ml. Transfections were performed in a 25 ml scale. Therefore, 25 µg plasmid DNA were diluted 
in culture medium to a total volume of 1.25 ml and vortexed shortly. 75 µg PEI were diluted in culture 
medium to a volume of 1.25 ml and treated equally. Afterwards, PEI-culture medium mixture was 
added to the DNA-culture medium mixture, vortexted and incubated at room temperature for 15 min. 
Transfection mixture was added cautiously in droplets to the cells. After about 24 hours, 700 µl of a 
20 % (w/v) trypton solution (in culture media) was added and cells were incubated for 4 more days at  
37 °C, 5 % CO2 and 100 rpm. Cells were incubated for four more days and supernatant was harvested 
by centrifugation (4500 g, 10 min, 4 °C). 
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Respective recombinant vNAR-Fc fusion proteins were purified by Protein A affinity chromatography 
using a HiTrap Protein A HP 1 ml column (GE Healthcare), equilibrated in Protein A chromatography 
running buffer, pH 7. For this, the supernatant was diluted with Protein A chromatography running 
buffer in a 2:1 ratio and injected onto the column. vNAR-Fc fusion protein was eluted using Protein A 
chromatography elution buffer, pH 3. To immediately neutralize acidic pH and thus, to minimize 
potential protein denaturation, 1 ml fractions were collected in tubes containing 200 µl of Protein A 
chromatography collection buffer, pH 9.0. Collected fractions were pooled and dialyzed (ZelluTrans, 
Carl Roth GmbH, MWCO 3500) against 5 L PBS, pH 7.4 for at least 3 hours at 8 °C and protein 
quality was assessed via SDS-PAGE (4.2.2). 
 
4.6 Characterization of vNAR proteins 
4.6.1 Determination of binding kinetics using the Octet RED96 System  
Biolayer interferometry (BLI) was used to determine the equilibrium dissociation constant (KD). All 
assays were performed on the Octet RED96 system (FortéBio). Affinities of target binding vNAR 
molecules were calculated with solitary vNAR domains, produced in E. coli as well as with vNAR-Fc 
fusion proteins, produced in human cell lines.  
For affinity calculation of solitary vNAR domains, measurements were performed with Streptavidin 
dip and read biosensors in kinetics buffer (PBS, pH 7.4, 0.1 % (w/v) BSA, 0.02 % Tween-20). 
Streptavidin dip and read biosensors were rehydrated for at least 30 min in PBS and put into the Octet 
Red96 device. Sensors were loaded with biotinylated vNARs at approx. 10 µg/ml. A target-unspecific 
vNAR was used as negative control and tested at the highest antigen concentration. For all 
measurements, kinetic data sets were fitted using 1:1 Langmuir binding via the manufacturer’s data 
analysis software with Savitzky-Golay filtering. 
For affinity assessment of vNAR-Fc fusions, measurements were performed with anti-human IgG Fc 
capture dip and read biosensors in kinetics buffer. Biosensors were rehydrated for at least 30 min in 
PBS and put into the Octet Red device. Sensors were loaded with Fc fusions at approx. 10 µg/ml. As 
negative controls, unspecific binding of target proteins to the biosensor tips was tested as well as 
unspecific binding of the immobilized vNAR-Fc fusion to an unrelated target protein.  
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4.6.2 Thermal shift assays 
Thermal shift assays were conducted to determine the Tm. Measurements were performed in 
quadruplicates on a BioRad 96CFX RT-PCR detection system with 0.5 °C/30 s to 99 °C. Tm values 
were obtained from melting curves using the corresponding BioRad analysis software. All reactions 
were performed in PBS, pH 7.4 in the presence of SYPRO Orange (diluted 1:1000, Sigma-Aldrich) 
and 0.1 mg/ml – 0.5 mg/ml protein. 
  
4.6.3 Cellular immunofluorescence assays 
Trypsinized cell lines MCF-7, EBC-1, T47D as well as CHO(s) were generously provided by Merck 
(EMD) Serono. For each antibody or vNAR-Fc concentration tested, approximately 5 x 10
5 
cells of the 
respective cell line were centrifuged and used for each antibody and vNAR staining. Assays were 
performed in a volume of 100 µl in PBS, pH 7.4 containing 1 % (w/v) BSA. Cells were first 
centrifuged (250 g, 4 °C, 10 min), and resuspended in different concentrations of α-EpCAM-vNAR 
5005 Fc fusion protein. Cells were stained for approximately 1 hour on ice. EpCAM-specific antibody 
clone HEA-125 conjugated to PE (MACS, Miltenyi Biotec) was used as positive control in a dilution 
of 1:11.  After washing the cells with ice-cold PBS, pH 7.4 containing 1 % (w/v) BSA, cells were 
incubated with anti-human IgG conjugated to PE (Fcγ-specific, eBioscience, diluted 1:30), except for 
EpCAM-specific antibody HEA-125. Cells were analyzed via FACS. 
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5. RESULTS 
5.1 Analysis of the natural vNAR repertoire of the bamboo shark (C. plagiosum) 
In a previous work tissues as well as blood samples were harvested from anesthetized bamboo 
sharks.[184] After total RNA isolation as well as reverse transcription, tissue-specific expression of 
IgNAR was analyzed via vNAR-specific amplification. It revealed that besides expression in blood, 
IgNAR is also found on the mRNA-level in the rectal gland, the skin, the liver, the stomach, the 
spleen, the kidney as well as in the gonads and in the epigonal organ.[184] 
To further gather information about the IgNAR V domain repertoire from non-immunized 
C. plagiosum, the diversity of the natural repertoire as well as the length distribution of CDR3 was 
examined (4.1). All respective deep sequencing subprojects within this work were carried out in 
cooperation with Andreas Christmann and Janine Becker (Technische Universität Darmstadt). For this, 
total RNA was isolated from whole blood of one specimen of the bamboo shark. Reverse transcription 
was executed using an Oligo(dT)18 primer. After gene-specific amplification using the primer 
combination bamboo/nat_up and bamboo/nat_lo, PCR products were pooled and the vNAR repertoire 
was analyzed using next-generation sequencing on the 454 GS Junior System platform (Roche) 
according to the manufacturer’s instructions. Consistent with literature,[109] deep-sequencing of the 
vNAR repertoire from blood circulating lymphocytes of one individual of C. plagiosum revealed that 
IgNAR V region diversity in this species is mainly CDR3 based (Fig. 13A). CDR1 along with HV2 
and HV4 only display minor sequence variations. The vast majority of approximately 92% of analyzed 
vNAR sequences had one cysteine residue within CDR3 and within CDR1, respectively, potentially 
forming an inter-loop disulfide linkage. Hence, the vNAR repertoire of the bamboo shark is considered 
to be mainly of type II, according to the categorization of vNAR domains based on the presence and 
absence of non-canonical disulfide bonds (2.5.2). As shown in Figure 13B, most of analyzed clones 
had a CDR3 with a length of 12 residues. However, a considerable fraction of clones contained a 
significantly prolonged length of 16 or more residues. A mean length of about 13 residues (12.8 aa) is 
substantially elongated compared to murine CDR3 sequences of the VH domain with a mean length of 
about 9 residues.[185] Surprisingly, the human CDR-H3 repertoire displays a broader length 
distribution from 1 to 35 residues compared to the bamboo shark (5-22 residues).[186] Still, the mean 
length of about 12 residues[185] is comparable with the mean length of CDR3 of the vNAR domain of 
C. plagiosum.   
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Figure 13. Analysis of the natural vNAR repertoire of the bamboo shark. (A) Consensus-sequence of the natural vNAR 
repertoire from non-immunized bamboo sharks. A set of approx. 1200 sequences was analyzed. The primer-mediated parts 
at the respective N-terminus and C-terminus are not shown. CDR1 is shaded blue, HV2 and HV4 are shaded red, and 
CDR3 is shaded green. Consensus of residues at each position is indicated by a black bar. (B) Length distribution of CDR3 
of the vNAR repertoire from a non-immunized bamboo shark. 
 
5.2 Construction of a semi-synthetic type IV bamboo shark vNAR library for yeast 
surface display 
Parts of this work have been published.[187] Results gained from the analysis of the primary vNAR 
repertoire of the bamboo shark had several consequences for the construction of the IgNAR V domain 
library for yeast surface display. We set out to construct a semi-synthetic type IV library using the 
natural PCR-amplified framework repertoire of C. plagiosum as starting material. Library construction 
on S. cerevisiae allows for the facile generation of more than 10
8
 clones. Taking this into 
consideration, we assumed that a total randomization of CDR3 using codon-based oligonucleotides 
almost certainly exceeds the natural diversity found in non-immunized animals. As a consequence, to 
extend natural vNAR diversity, we constructed the semi-synthetic vNAR library by polymerase chain 
reaction where in the framework of the natural vNAR repertoire CDR3 was totally randomized. This 
was achieved by the incorporation of trinucleotide mixtures encoding 19 amino acids except cysteine 
into the corresponding oligonucleotide. Framework regions and the hypervariable loops were used 
from non-immunized repertoires of a cohort of three bamboo sharks. In analogy to the natural 
repertoire (Fig. 13B) we designed the CDR3 to comprise 12 randomized residues.  
For library construction total RNA was isolated from whole blood of three individuals and used as 
template for cDNA synthesis using the Omniscript® Reverse Transcription Kit (Qiagen) and OdT-
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Oligonucleotides (4.2.1). From each individual three reactions were processed in parallel, each 
containing approximately 2 µg of RNA. From each reaction 5 µl were used for the follow-up gene-
specific amplification. The pooled PCR amplified naïve vNAR products were used as starting material 
for the semi-synthetic library construction. The initial library was established in three consecutive 
PCR-steps (Fig. 14B). In the first reaction PCR amplified vNAR product from the natural repertoire 
was used as template (approximately 200 ng) with the primer combinations FR1/CDR1/Tyr_up and 
FR3_lo. The forward primer replaced Cys by Tyr and incorporated a marginal diversity within CDR1 
to resemble the natural sequence variation found in this region (Fig. 13A). Subsequently, the second 
PCR was performed to fully randomize CDR3 using the primer-combination FR1_up and 
CDR3/rand/FR4_lo. Afterwards, this particular PCR product was used as a template for the third 
reaction using primers with overlaps up- and downstream of the Nhe I and Bam HI restriction sites of 
the pCT-plasmid[150], respectively (GR_up and GR_lo). Accordingly, the pCT vector was digested 
with Nhe I and Bam HI. Library was established via an improved yeast transformation method 
according to Benatuil et al. in a homologous recombination-based process referred to as plasmid gap 
repair.[181] For electroporation 1-2 µg of the digested plasmid and 6-8 µg of insert were used.  
Two days after transformation, the library size was calculated by dilution plating and yielded in a 
library diversity of approximately 2 x 10
8
 unique clones. Library-encoded IgNAR V domains were 
displayed on the yeast cell surface via fusion to cell wall protein Aga2p, which is anchored to the cell 
wall by association with Aga1p.[150] The vNAR molecules were flanked by a HA-tag and cMyc-tag 
at the N-terminus and C-terminus, respectively, for detection of surface-exposed vNAR (Fig. 14A). 
Surface presentation of vNAR variants (4.3.1) was characterized by indirect fluorescence labeling of 
the cMyc-epitope and HA-tag (Fig. 14C and D). Within three days post-induction, there was nearly 
total HA-tag expression of the library detectable and nearly 90% of cMyc-labeling, both indicating 
expression and high copy number display of vNAR domains on the surface of S. cerevisiae.  
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Figure 14. Library construction and analysis. (A) Illustration of vNAR yeast surface display.[149] vNARs are presented on 
the surface of S. cerevisiae as Aga2p fusions with an N-terminal HA-epitope and a C-terminal cMyc-tag, respectively, for 
the detection of surface expression. (B) Schematic representation of PCR-based library design. PCR amplified vNAR 
fragments from blood circulating lymphocytes of a cohort of three bamboo sharks were used as template. In a first PCR the 
framework was amplified. The cysteine residue in CDR1 was replaced by tyrosine and a marginal diversity was introduced 
via the forward primer. In a subsequent reaction the total vNAR molecule was constructed and an artificial CDR3 was 
introduced. The 3
rd
 reaction was carried out to incorporate homologous sites for gap repair cloning. Histogram of cMyc (C) 
and HA-tag (D) surface expression of the constructed vNAR library assessed by indirect immunofluorescence labeling and 
flow cytometry. Grey: negative control (cells after 3 days induction of gene expression) labeled with detection reagents 
only; black: immunofluorescence staining after 3 days induction of gene expression.  
 
To further evaluate library quality, the distribution of amino acids and the codon usage in the artificial 
CDR3 were assessed via deep sequencing (4.1, Fig. 15). 8220 positions from 685 unique vNAR 
sequences with a CDR3 of 12 residues were analyzed on the 454 GS Junior System platform (Roche) 
according to the manufacturer’s instructions. The horizontal bar shown in Figure 15 depicts the 
distribution of 5.26 % for each amino acid residue in an ideally unbiased library (Fig. 15). The residue 
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overrepresented by more than 2 % was Lys with a frequency of 8.37 %. The residues underrepresented 
in this library by more than 2 % were Phe and Val with frequencies of 3.24 % and 3.08 %, 
respectively. Albeit not considered for library design, Cys residues and stop codons were present in 
CDR3 with frequencies of 0.49 % and 0.1 %. Those findings may originate from mistakes during deep 
sequencing procedures or to a marginal fraction of wild-type vNAR CDR3. 
 
Figure 15. Distribution of amino acids in CDR3 of the unselected library. A total number of 685 unique sequences were 
analyzed (8220 positions). X, Stop-codon. The horizontal bar marks the expected representation for all 19 residues of an 
ideally unbiased library.  
 
5.3 Selection of antigen binding semi-synthetic vNAR domains 
The established vNAR library was subjected for library screening to select for mono-specific target 
binding molecules (4.3.4). Screening was conducted against EpCAM, EphA2 and Interleukin-8 (the 
latter in cooperation with Julius Grzeschik during his master-thesis). Additionally, antigen binding 
vNAR molecules were also selected to target human serine protease HTRA1, executed by Niklas 
Weber. Detailed data for the HTRA1 screening will be provided by Niklas Weber in his PhD thesis 
and can also be found elsewhere.[187] 
 
5.3.1 Screening against epithelial cell adhesion molecule (EpCAM) 
Recombinant human EpCAM (CD326) was purchased from AcroBiosystems. The protein consists of 
the EpEX domain (amino acids Gln 24 – Lys 265) fused to a poly-histidine tag at the C-terminus. The 
molecular weight is calculated to be 29 kDa. Due to glycosylation it migrates at 33-36 kDa. 
All initial FACS sorting rounds were performed with 1 µM EpCAM. Target binding was detected by 
indirect immunofluorescence using either Alexa Fluor 488 labeled anti-His-tag antibody or using 
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biotinylated target protein followed by cell staining with streptavidin-allophycocyanin conjugate. All 
screening rounds were performed to simultaneously select for full-length vNAR presentation using 
myc-staining and for target binding. In the first round of sorting approximately 2 x 10
8
 cells were 
screened (Fig. 16, left). Antigen binding was monitored via Alexa Fluor 488 labeled anti-His-tag 
antibody. After each sorting round, collected cells were immediately subjected for a resort to enhance 
stringency. To avoid off-target binding against detection reagents the labeling strategy was alternated 
from Penta-His antibody to biotinylated EpCAM after the first round of screening. Subsequent library 
screening in sorting rounds two and three revealed a significant enrichment of antigen binding 
populations (Fig. 16, middle and right).   
 
Figure 16. Library screening against EpCAM. Sorting gates and target concentrations are shown. Yeast cells were labeled 
for simultaneous detection of surface presentation and antigen binding. After each round a resort was performed. Cells in 
the sorting gate were isolated, grown and induced for the next round of selection. Percentage of cells in sorting gate: (R1) 
0.17 %; (R2) 1.03 % and (R3) 8.04 %.  
 
Single clones were analyzed for antigen binding (4.3.2) using 1 µM EpCAM an FACS-positive clones 
were sent out for sequencing. Ten unique EpCAM-binding vNAR clones were identified (Fig. 17). 
 
Figure 17. Sequences of EpCAM binding vNAR molecules selected from initial library screen. Dots indicate identical 
residues. CDR1 and CDR3 are shaded in blue and green, respectively. 
 
Five clones were randomly chosen and more deeply characterized in terms of affinity via equilibrium 
dissociation constant determination on the yeast surface (4.3.3, Tab. 2). Affinity titration revealed 
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equilibrium binding constants for EpCAM binding clones in the triple-digit nanomolar to single-digit 
micromolar range, with an average affinity of 0.7 µM. 
 
Table 2. Equilibrium dissociation constants (KD) determined by yeast surface display. 
vNAR clone target screen KD [nM] 
H2 EpCAM initial 741 ± 267 
H3 EpCAM initial 1301 ± 616 
H5 EpCAM initial 1030 ± 524 
H8 EpCAM initial 212 ± 161 
H10 EpCAM initial 301 ± 187 
mmE1 EphA2 initial 368 + 144 
mmE2 EphA2 initial 482 + 334 
I1 IL-8 initial > 3300  
 
5.3.2 Screening against receptor tyrosine kinase EphA2 
Recombinant human receptor tyrosine kinase EphA2 was purchased from R&D Systems. The protein 
consists of amino acids Gln25 - Asn534 and is fused to a C-terminal his-epitope. It has a predicted 
molecular mass of 56.9 kDa. Recombinant murine EpCAM was purchased from Sino Biological Inc. 
The extracellular domain (Met1 - Asn535) is fused to a His-eptitope at the C-terminus and has a 
predicted molecular weight of 58 kDa.  
All screenings (4.3.4) were performed using 1 µM of EphA2. In all rounds we simultaneously selected 
for full-length vNAR presentation using myc-staining and for target binding. Akin to screening against 
EpCAM, after each round of screening, a resort was carried out. In the first round of screening, 
approximately 1.5 x 10
8
 cells were sorted using indirect immunofluorescence via Alexa Fluor 488 
labeled anti-His-tag antibody (Fig. 18, upper row). After sorting round 1 biotinylated target protein 
was used for consecutive screening rounds. In screening round 3, a target binding population was 
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detected. Consequently, single clones were analyzed for antigen binding. EphA2-binding clones were 
sent out for sequencing and four different EphA2-specific vNAR were identified (Fig. 19).  
For the isolation of IgNAR V domains that bind both human and murine EphA2, which may be useful 
for animal studies, the population enriched for EphA2 binders (after sort 3) was subjected to two more 
rounds of selection via YSD using murine EphA2 as antigen (Fig 18, lower row). Surprisingly, in 
spite of alternated screening from his-tagged EphA2 and Alexa Fluor 488 labeled anti-His-tag 
antibody to biotinylated antigen, a distinct population of anti-His-tag antibody binding clones was 
detected in round 4 (Appendix A). To avoid the isolation of this particular population, the sorting gate 
was accordingly adjusted. The resort of this round showed that there was no significant enrichment of 
off-target binding clones (Fig. 18, lower row, middle). Along with this finding, in the fifth round 
biotinylated murine EphA2 was used for screening. After this round, single clones were analyzed for 
binding murine and human EphA2 (4.3.2). This resulted in two vNARs with the desired promiscuous 
specificity (Fig. 19).  Affinities for both, human and murine EphA2 binding clones were characterized 
via affinity-titration on the yeast surface (4.3.3) using human EphA2 as antigen, resulting in an average 
affinity of around 0.4 µM (Tab. 2).  
 
Figure 18. Library screening against EphA2. Sorting gates and target concentrations are shown. Yeast cells were labeled 
for simultaneous detection of surface presentation and antigen binding. After each round a resort was performed. Cells in 
the sorting gate were isolated, grown and induced for the next round of selection. Percentage of cells in sorting gate: (R1) 
0.11 %; (R2) 0.10 % and (R3) 6.87 %. In round 4 and 5 murine EphA2 (mm) was used as antigen. Percentage of cells in 
sorting gate: (R4) 2.43 % and (R5) 1.01 %. 
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Figure 19. Sequences of EphA2 binding vNAR molecules selected from initial library screen. Dots indicate identical 
residues. CDR1 and CDR3 are shaded in blue and green, respectively. rh: vNAR molecules selected from screen against 
recombinant human EphA2. mm: clones selected after two additional rounds of screening against murine EphA2, 
promiscuous specificity for human and murine EphA2 was validated via yeast surface display. 
 
5.3.3 Screening against human interleukin-8 
The isolation (and affinity maturation) of Interleukin-8 binding vNARs was carried out in cooperation 
with Julius Grzeschik during his Masterthesis. Detailed data on the isolation and characterization can 
be found elsewhere.[188] Yet, main findings will be described within this subsection.  
Interleukin-8 was provided by the working group of Prof. Schmitz, TU Darmstadt. The 8.3 kDa 
molecule was expressed in E. coli and purified by anion exchange chromatography, followed by size 
exclusion chromatography and HPLC on a RP-8 column. Target protein quality was assessed via SDS-
PAGE and revealed no proteolytic degradation of IL-8 and no significant impurities. Since the 
provided IL-8 did not have any affinity-tag or epitope for the detection via indirect 
immunofluorescence, only biotinylated IL-8 was used for screening experiments. However, to avoid 
off-target binding, detection of target binding was alternated from streptavidin-APC (or streptavidin-
PE) to avidin-FITC. Both detection reagents display high-affinity binding to biotin, though sequence 
identity is very low, minimizing the chance for the enrichment of binders against secondary detection 
reagents.  
For the isolation of IL-8 binding clones, 2 µM was used for every screening round (4.3.4). In the first 
screening round approximately 4 x 10
8
 cells were sorted. Labeling for antigen binding was carried out 
using avidin-FITC and alternated to streptavidin-APC for the second and third screening round. The 
first three screening rounds were performed via double-labeling. In the fourth round, double-labeling 
for simultaneous detection of full-length presentations and antigen binding was omitted since cMyc 
surface expression was about 75 %. As shown in Figure 20 we were able to enrich for CXCL8 binding 
vNAR populations within four rounds of screening (Fig. 20). Single clones were analyzed for antigen 
binding (4.3.2) and FACS-positive clones were sent out for sequencing, resulting in two unique 
sequences (Fig. 21). Since CDR3 of single clone I2 mainly comprised hydrophobic amino acids, this 
clone was considered to be unspecific and not further scrutinized. Single clone I1 was characterized in 
terms of affinity on the yeast surface (4.3.3) which resulted in a moderate equilibrium binding constant 
in the single-digit micromolar range (Tab. 2). 
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To this end, binders isolated against all different targets (including HTRA1, not shown) displayed low 
to moderate affinities in the triple-digit nanomolar to single-digit micromolar range (for HTRA1 also 
in the double-digit micromolar range). To improve affinities substantially, a new methodology for 
affinity maturation was employed, as described in the following section. 
 
Figure 20. Fourth round of library screening against IL-8. Sorting gate and target concentration are shown. Yeast cells 
were labeled for antigen binding. Percentage of cells in sorting gate: 9 %. 
 
 
Figure 21. Sequences of IL-8 binding vNAR molecules selected from initial library screen. Dots indictate identical 
residues. CDR1 and CDR3 are shaded in blue and green, respectively. 
 
5.4 Affinity maturation of target-enriched semi-synthetic vNAR domains 
To enhance affinities of the selected antigen binding vNAR populations, a new methodology for 
affinity maturation was established that resembles the natural immune response in sharks. As 
mentioned in the introduction (2.2.3, 2.5.3), the primary vNAR repertoire of sharks is mainly restricted 
to CDR3. However, due to somatic hypermutation, after antigen contact, the vNAR domain further 
diversifies with mutations clustering to the CDRs and hypervariable loops. Furthermore a significant 
bias towards replacement substitutions is observed in CDR1.[109] To mimic this natural process, we 
decided to diversify five residues within CDR1 of vNAR molecules enriched after FACS-screening by 
constructing sublibraries. The design of these sublibraries for affinity maturation was based on the 
enriched target binding vNAR populations against EpCAM and HTRA1 (not shown within the scope 
of this thesis), respectively, which were obtained after three screening rounds. For Interleukin-8, only 
clone I1 was used as starting material for sublibrary design. As a consequence, for each target a 
particular sublibrary was constructed (4.2.2).  
To this end, DNA was isolated from the enriched population or from the respective single clone and 
used as a template for the randomization of five residues in CDR1. Akin to randomization of CDR3 of 
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the initial library, diversifications were performed by incorporation of triplet codons into the 
corresponding oligonucleotide. For affinity maturation of the enriched antigen binding population or 
single clone plasmid-DNA was isolated from yeast cells after sorting the cells via FACS and 
incubation at 30 °C for two days. Sublibraries with totally randomized CDR1 were constructed in a 
consecutive 3-step PCR. Randomization of CDR1 was similar to the initial library establishment 
(Fig. 14A). In the first PCR reaction, the primer pair CDR1rand_up/GR_lo was used to randomize 
CDR1 followed by two subsequent PCR reactions with primer pairs FR1_up/GR_lo and 
GR_up/GR_lo, respectively. For affinity maturation of α-EpCAM-vNARs and α-IL-8-vNARs, 
libraries for yeast surface display were established according to initial library construction, as 
described in chapter 5.2. This yielded in a library diversity of approximately 2 x 10
8
 unique clones for 
α-EpCAM-sublibrary and about 108 clones for α-IL-8-sublibrary, as determined by dilution plating. 
Since the theoretical diversity in a total randomized loop of five residues is approximately 2.5 x 10
6
, 
library construction for both sublibraries was considered to almost ensure full coverage of all 
theoretical variants.   
 
5.4.1 Sublibrary screening for the isolation of EpCAM binding vNARs with enhanced 
affinities 
To obtain target binders with higher affinities, the EpCAM-sublibrary was subjected to FACS-
screening using yeast surface display with significantly reduced target concentrations (4.3.4). Whereas 
the initial library was screened using 1 µM of EpCAM, in the first round of sublibrary screening only 
50 nM of target was used (Fig. 22). In the second round of sorting, target concentration was once more 
step-wise reduced, aimed at enhancing selection stringency. Moreover, staining was alternated from 
Alexa Fluor 488 labeled anti-His-tag antibody staining to biotinylated antigen, to avoid enrichment of 
off-target binders. To isolate a multitude of affinity-enhanced binders and to avoid out-competition of 
binders, the target concentration was increased to 50 nM for α-EpCAM CDR1 affinity maturation in 
the last screening round. As shown in Figure 18 a target binding population under enhanced selection 
stringency was enriched after round 2 and approximately 47 % target-positive cells were enriched in 
the last screening round (Fig. 22). Single clone analysis (4.3.2) and subsequent sequencing of 
target-positive variants revealed six different EpCAM-binders (Fig. 23). Interestingly, EpCAM-
binding clones 1017, 5005 and R23 contained the same CDR3 as EpCAM-binding clone H3 from 
initial screenings. However, CDR1 was unique in all of those clones, respectively. In addition, clones 
1013, 1014 and R31 showed novel and unique CDR3 loops, which have not been identified after 
sequencing of binders from the initial library. 
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Figure 22. Screening of an α-EpCAM sublibrary after randomization of CDR1. Sorting gates and target concentrations are 
shown. Yeast cells were labeled for simultaneous detection of surface presentation and antigen binding (in Maturation 
Round 3, double labeling was omitted since vNAR cMyc surface expression was > 90%). After each round a resort was 
performed. Cells in the sorting gate were isolated, grown and induced for the next round of selection. Target-positive cells 
after affinity maturation in sorting gate: (MR1) 0.1 %; (MR2) 4.8 % and (MR3) 47.2 %. 
 
 
Figure 23. Sequences of selected α-EpCAM-vNARs after CDR1 randomization aligned to initially selected vNAR H3. 
Dots indicate identical residues. CDR1 and CDR3 are shaded in blue and green, respectively. 
 
Five out of six clones against EpCAM after CDR1 affinity maturation were randomly selected for 
yeast cell surface affinity titration (4.3.3, Tab. 3). All EpCAM binders exhibited high-affinity binding 
in the low nanomolar range. The average affinity was 11.2 nM, which corresponds to an enhancement 
of affinity by the factor of 65 compared to the clones obtained prior to affinity maturation (Tab. 2). 
These findings clearly highlight the contribution of CDR1 to antigen binding. 
 
5.4.2 Sublibrary screening for the isolation of CXCL8 binding vNARs with enhanced 
affinities 
The established α-IL-8 sublibrary was screened, aimed at enriching CDR1-diversified variants with 
significantly enhanced affinities (4.3.4). For this, the target protein was step-wise reduced within 
successive screening rounds (Fig. 24). In this particular case, due to starting with one single-clone for 
sublibrary design and not with a whole population, there was no need for alternated screening, since 
enrichment of off-target binding clones against detection reagents could be excluded. Hence, in this 
particular affinity maturation procedure, antigen binding was exclusively detected using streptavidin-
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APC. To maximize selection stringency the fourth round of sorting was performed in two parallel 
screening experiments with 25 nM and 10 nM, respectively (Fig. 24, lower row).  
 
Figure 24. Screening of an α-IL-8 sublibrary after randomization of CDR1. Sorting gates and target concentrations are 
shown. Yeast cells were labeled for simultaneous detection of surface presentation and antigen binding. Cells in the sorting 
gate were isolated, grown and induced for the next round of selection. Target-positive cells after affinity maturation in 
sorting gate: (MR1) 0.8 %; (MR2) 2.5 %; (MR3) 1 %; (MR4, 25 nM) 0.93 % and (MR4, 10 nM) 0.24 %. 
 
After the respective fourth round, single clones were analyzed for antigen binding (4.3.2) and FACS-
positive clones were sent out for sequencing, which resulted in the identification of four vNARs, all 
comprising CDR3 of the parental molecule I1, but a unique CDR1 (Fig. 25). Affinities of all clones 
after affinity maturation were determined on the surface of the yeast via affinity titration (4.3.3) and 
exhibited significantly enhanced affinities compared to the parental molecules (Tab. 3). The best 
clone, referred to as I25.3, showed an affinity of about 430 nM, which corresponds to an enhancement 
of affinity by the factor of 7.6.   
 
 
Figure 25. Sequences of selected α-IL-8-vNARs after CDR1 randomization aligned to initially selected vNAR I1. Dots 
indicate identical residues. CDR1 and CDR3 are shaded in blue and green, respectively. 
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Table 3. Equilibrium dissociation constants (KD) determined by yeast surface display after affinity maturation. 
vNAR clone target screen parental CDR3 KD [nM] 
1013 EpCAM CDR1mat n.d. 7 ± 3 
1014 EpCAM CDR1mat n.d. 5 ± 2 
1017 EpCAM CDR1mat H3 6 ± 3 
5005 EpCAM CDR1mat H3 14 ± 7 
R23 EpCAM CDR1mat H3 24 ± 9 
I25.2 IL-8 CDR1mat I1 520 ± 75 
I25.3 IL-8 CDR1mat I1 432 ± 54 
I25.6 IL-8 CDR1mat I1 ~ 750  
I3.1 IL-8 CDR1mat I1 ~ 1000  
KDs after affinity maturation (CDR1mat) are shown for different targets. Parental CDR3: 
CDR3 of binders after affinity maturation resulting from a clone of the initial library screen. 
n.d.: CDR3 was not found after sequencing of binders selected from initial screen.  
 
5.5 Expression of selected vNAR domains 
Previous work of Wittrup and colleagues showed that the dissociation constant calculated by affinity 
titration on the yeast surface correlates well with measurements of soluble protein.[146,189] To 
examine if this correlation is also consistent for vNAR domains selected by yeast surface display and 
also to assess thermal stability, we chose EpCAM binders H3 and H5, obtained from initial screenings 
with micromolar affinities as well as nanomolar EpCAM binder 5005, identified after CDR1 affinity 
maturation, for protein production in E. coli (4.4). The respective vNAR molecules were expressed in 
the pMX vector[183] that introduces maltose binding protein (MalE) and a hexahistine tag for fusion 
protein expression and purification. A scheme for protein production is depicted in Figure 26 
(Fig. 26). IgNAR V domains were expressed as MalE-fusion proteins with a triple alanine linker and 
cleavage site for tabacco etch virus protease (TEV) as well as a C-terminal triple alanine linker and 
hexa-histidine tag. vNARs were first purified using nickel affinity chromatography (IMAC), followed 
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by TEV-protease cleavage. The monomeric vNAR domains were further purified and isolated by gel 
filtration chromatography.   
 
 
 
Figure 26. Scheme of of recombinant vNAR domain production as MalE-fusion protein. Ala(3): Triple alanine linker; 
His(6): hexahistidine-tag for protein purification; TEV site: site for specific cleavage by tabacco etch virus protease (TEV). 
IMAC purified protein was first digested via TEV protease and in a final step purified using GFC. 
 
pMX vector, containing for E.coli codon-optimized α-EpCAM-vNAR DNA-sequences for variant 
5005 was purchased from GeneArt (Life Technologies). Codon-optimization was performed according 
the manufacturer’s software. For protein production (4.4.1) of αEpCAM-vNAR_H3 and 
α-EpCAM-vNAR_H5, the respective DNA fragment was PCR amplified using primer-combination 
pMX_vNAR_up/pMX_vNAR_lo and isolated total DNA from S. cerevisiae single clones H3 or H5, 
containing the plasmid DNA as template. Afterwards, PCR-product as well as pMX-vector was 
digested using Acc 65I and Xba I. After gel-purification, PCR-products were ligated into pMX vector. 
Electro-competent E. coli BMH 71-18 cells were transformed with plasmids pMX_αEpCAM-
vNAR_H3, pMX_αEpCAM-vNAR_H5 and pMX_αEpCAM-vNAR_5005, respectively. 
E. coli BMH 71-18 cells containing the respective plasmid were grown to an OD600 between 0.7 and 1 
in 2 L dYT medium containing 25 mg/L chloramphenicol and protein production was induced with 
1 mM IPTG. Cells were grown overnight (approx. 16 h) at 29 °C and harvested by centrifugation 
(4.4.2). The periplasmic fraction containing the respective MalE-vNAR fusion-protein was isolated. 
Respective recombinant vNAR proteins were purified by metal chelate affinity chromatography 
(HisTrap, GE Healthcare), equilibrated in PBS, pH 7.4. Proteins were eluted using a linear imidazole 
gradient starting from 0 % to 100 % of 1 M imidazole over 30 min (Fig. 27). The different vNAR 
proteins eluted at concentrations ranging from approximately 100 mM imidazole to 200 mM 
imidazole. MalE-vNAR fusion-proteins have a calculated molecular mass of approximately 57.5 kDa. 
As shown at Figure 27 produced fusion-proteins migrate in the gel between 46 kDa and 58 kDa, 
correlating with the predicted molecular weight. Collected fractions shown on the gel were pooled for 
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each respective vNAR domain (Fig. 27). After this first purification step, fusion proteins were cleaved 
via tabacco etch virus protease cleavage overnight at 4 °C to isolate the solitary vNAR products.  
 
Figure 27. Elution profile of selected and recombinant produced MalE-vNAR fusion-proteins on a His Trap HP 1 ml 
column equilibrated in PBS, pH 7.4 and run with a flow rate of 1 ml/min. Blue: Absorption at 280 nM. Pink: Injection. 
Green: Imidazole gradient (0 % - 100 % of 1 M imidazole over 30 min). Red: Collected fractions.  Corresponding gels of 
SDS-PAGE of collected fractions are shown. F: Flow-through. Numbers indicate collected fractions of the corresponding 
IMAC run. Chromatogram and gel (SDS-PAGE) of vNARs H3 (A), H5 (B) and 5005 (C).  
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Finally, proteins were purified to remove TEV-protease as well as MalE-protein using gel filtration on 
either a Superdex 200 pg 16/60 or on a Superdex 75 pg 16/60 (GE Healthcare), equilibrated in PBS, 
pH 7.4 (Fig. 28). The peak corresponding to the solitary vNAR domain was collected and concentrated 
using Amicon® Ultra-15 centrifugal filter devices (Merck Millipore Ltd.). Protein quality was 
assessed via SDS-PAGE indicating highly purified solitary vNAR proteins, migrating between 7 kDa 
and 17 kDa which is consistent with the predicted molecular mass of about 13.2 kDa.  
 
Figure 28. Purification of recombinant vNAR proteins via size exclusion chromatography (A-C) and quality control of 
purified vNAR products using SDS-PAGE (D). (A) Elution profile of IMAC-purified TEV-cleaved vNAR 5005 protein on 
a Superdex 200 pg 16/60 equilibrated in PBS, pH 7.4 and run with a flow rate of 1 ml/min. Elution profile of IMAC-
purified TEV-cleaved vNAR H5 (B) and H3 (C) protein on a Superdex 75 pg 16/60 equilibrated in PBS, pH 7.4 and run 
with a flow rate of 1 ml/min. (D) Gel of SDS-PAGE of solitary vNAR domains following gel filtration. 
 
Protein concentrations were determined on a photometer (Biospec-nano, Shimadzu), showing 
moderate yields for vNAR production as fusion-proteins following a two-step purification procedure 
with an additional manipulation step via TEV-protease cleavage. Although yields for α-EpCAM-
vNAR 5005 were sufficient (approximately 1.1 mg/L), α-EpCAM-vNARs H3 and H5 were only 
produced in low amounts of about 0.3 mg/L and 0.6 mg/L, respectively.  
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5.6 Formatting of α-EpCAM-vNAR 5005 as Fc-fusion 
To enhance vNAR expression, α-EpCAM-vNAR 5005 was genetically fused to the N-terminus of a 
human Fc domain (4.5). The rationale was that fusions to the human Fc-part, besides enhancing vNAR 
expression yields and causing the formation of dimers, can also elicit in vivo immune effector 
functions via ADCC and CDC. Moreover for cell-based immunofluorescence assays, binding of Fc-
fusion proteins to cells e.g. tumor cells can easily be detected using fluorescently-labeled secondary 
antibodies targeting the human Fc-part.  
For this, α-EpCAM-vNAR 5005 was expressed in the pExpress vector that introduces the human Fc-
part. At first, α-EpCAM-vNAR 5005 was amplified using isolated pCT_αEpCAM-vNAR_5005 as 
template (4.5.1). The hinge-region was introduced in a consecutive two-step PCR with primer pair 
pEXPR_vNAR_up/pEXPR_vNAR_loI and pEXPR_vNAR_up/pEXPR_vNAR_loII, respectively. 
PCR product as well as pEXPR were digested using Nhe I and Apa I and the digested vNAR product 
was ligated into the pEXPR vector. Expi293F™ cells were transfected with 
pExpress_αEpCAM-vNAR_5005 using the Expi293™ Expression System Kit (Life Technologies) 
and cells were cultured at 37 °C, 5 % CO2 (in air) and 100 rpm (4.5.2). After approximately 24 hours 
150 µl of ExpiFectamine™ 293 transfection enhancer 1 and 1.5 ml ExpiFectamine™ 293 transfection 
enhancer 2 were added. Five days post transfection the suspension was centrifuged, cells were 
discarded and the supernatant containing the secreted vNAR-Fc fusion was harvested. Purification of 
vNAR-fusion protein was executed via Protein A affinity chromatography using a HiTrap Protein A 
HP 1 ml column (GE Healthcare), equilibrated in Protein A chromatography running buffer, pH 7 
(Fig. 29). vNAR-Fc fusion protein was eluted using Protein A chromatography elution buffer, pH 3. 
To immediately neutralize acidic pH and thus, to minimize potential protein denaturation, 1 ml 
fractions were collected in tubes containing 200 µl of Protein A chromatography collection buffer, 
pH 9.0. Collected fractions were pooled and dialyzed against 5 L PBS, pH 7.4 overnight at 8 °C and 
protein quality was assessed via SDS-PAGE (Fig. 29). The vNAR-Fc fusion has a predicted molecular 
mass of about 43 kDa. The eluted protein migrates between 30 kDa and 46 kDa, which is consistent 
with the calculated molecular mass. The concentration of the protein was determined photometrically 
(Biospec-nano, Shimadzu) yielding in approximately 192 mg/L indicating high-level expression of 
vNAR-Fc fusion proteins in mammalian cells. 
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Figure 29. Elution profile of α-EpCAM_vNAR 5005-Fc fusion protein on a HiTrap Protein A HP 1 ml column equilibrated 
in Protein A chromatography running buffer, pH 7 and run with a flow rate of 1 ml/min. Blue: Absorption at 280 nM. Pink: 
Injection. Green: Protein A chromatography elution buffer concentration, pH 3 (%). Red: collected fractions.  
Corresponding gel of SDS-PAGE of pooled fractions is shown.  
 
5.7 Characterization of selected vNAR domains 
Soluble produced vNAR domains as well as formatted vNAR-Fc fusion protein were characterized in 
terms of affinity, selectivity and stability (4.6). Affinities of all produced vNARs were assessed using 
biolayer interferometry (FortéBio) and for the examination of thermal stability thermal shift assays 
were retrieved. Selectivity of α-EpCAM-vNAR 5005, its parental molecule α-EpCAM-vNAR H3 and 
of α-EpCAM-vNAR H5 were studied on the yeast surface. Off-target binding was analyzed with 
selected unrelated target proteins. Finally, formatted α-EpCAM-vNAR_5005-Fc fusion was used for 
tumor cell staining assays.  
 
5.7.1 Affinity measurements using biolayer interferometry  
The equilibrium dissociation constant (KD) for all produced vNAR variants was determined on the 
Octet RED96 system (4.6.1). For solitary vNAR domains all assays were performed with Streptavidin 
Dip and Read™ biosensors in kinetics buffer. Sensors were loaded with biotinylated vNARs at 
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approximately 10 µg/ml. As negative control, a target-unspecific vNAR was used. Formatted 
α-EpCAM-vNAR 5005-Fc fusion was measured using Anti-Human IgG Fc Capture Dip and Read™ 
biosensors and the fusion protein was loaded at approximately 10 µg/ml (Fig. 30). Kinetic data sets 
were fitted using 1:1 Langmuir binding via the manufacturer’s data analysis software with Savitzky-
Golay filtering. 
 
Figure 30. Binding curves of α-EpCAM vNARs used to determine KD values via biolayer interferometry on the Octet
®
 
RED96 System. For all measurements, vNAR was immobilized on the tip surface. All vNARs except for the Fc-fusion 
were biotinylated. Correspondingly, Streptavidin Dip and Read™ biosensors were used. Anti-Human IgG Fc Capture Dip 
and Read™ biosensors were used for Fc-fusion measurements. For vNARs H3 and H5 measurements EpCAM 
concentrations of 5 µM, 4  µM, 3  µM, 2  µM, 1 µM and 0,75 µM were employed. Solitary vNAR 5005 was measured in 
500 nM, 250 nM, 125 nM, 62.5 nM, 31.25 nM and 15.625 nM. Negative control with unrelated vNAR were tested at the 
highest respective concentration and subtracted from each curve. α-EpCAM vNAR 5005 Fc-fusion was measured in 
67.5 nM, 33.8 nM, 8.4 nM, and 4.2 nM EpCAM. Negative control: kinetics buffer. 
 
As shown in Table 4, dissociation constant calculated by affinity titration on the yeast surface 
correlates well with measurements of soluble protein (Tab. 2, Tab. 3 and Tab. 4). Binder 5005 
showed an approximately 40-fold enhanced affinity compared to the parental vNAR H3. Both, 
improvements in on-rate kinetics (5-fold) as well as in off-rate kinetics (8.1-fold) contributed to the 
enhanced dissociation constant. Formatting of vNARs as Fc fusion proteins does not negatively affect 
binding kinetics. Compared to the solitary vNAR 5005, we observed a marginal increased association. 
Additionally, there is evidence, that dimerization of vNAR 5005 mediated by the Fc part likely 
contributes to a significantly enhanced Koff compared to the solitary monomeric vNAR domain, 
causing a moderately improved equilibrium dissociation constant by the factor of about 3 (Tab. 4). 
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Table 4. Binding kinetics and Tm of soluble vNAR variants selected against EpCAM. 
vNAR 
clone 
Target Screen parental 
CDR3 
Kon  
(M
-1
s
-1
) 
Koff 
 (s
-1
) 
KD 
[nM] 
Tm 
 [°C] 
H3 EpCAM initial - 6.0 x 10
4
 8.9 x 10
−2
 1495 75.1 ± 0,5 
H5 EpCAM initial - 4.3 x 10
4
 1.0 x 10
−1
 2342 71.5 ± 0,6 
5005 EpCAM CDR1mat H3 3.0 x 10
5
 1.1 x 10
−2
 37 64.9 ± 0,6 
5005-Fc EpCAM CDR1mat H3 3.4 x 10
5
 4.6 x 10
−3
 13 - 
Binding kinetics measured on the Octet
®
 RED96 System. Tm determined via thermal shift 
assays.  
 
5.7.2 Determination of thermal stability  
The thermal stability of all three monomeric vNAR molecules was explored in thermal shift assays 
(4.6.2) on a BioRad 96CFX RT-PCR detection system using SYPRO Orange to obtain the melting 
temperature (Fig. 31, Tab. 4).Tm values varied from approximately 65 °C to over 75 °C, indicating a 
high thermal stability, with binder 5005 possessing the lowest Tm of 64.9 °C. However, its parental 
molecule, H3 showed the highest thermal stability (Tm = 75.1 °C), indicating that in this particular 
case enhancement of affinity is at the cost of thermal stability. 
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Figure 31. Thermal shift assays for Tm calculation of α-EpCAM vNARs. Melt peaks are shown for each individual 
vNAR. Quadruplicates were conducted to determine the standard deviation.  
 
5.7.3 Determination of selectivity with related and unrelated target proteins using yeast 
surface display 
Specificity of α-EpCAM-vNAR H3 and H5, isolated from initial screening as well as α-EpCAM-
vNAR 5005 obtained after affinity maturation was scrutinized on the yeast surface (4.3.2) with three 
unrelated target-proteins, tGFP, murine EGFR and EphA2. Additionally, binding against murine 
EpCAM was assessed. For this, single clones were incubated with 1 µM of the respective related or 
unrelated target protein.  
As shown in Figure 32, no off-target binding was detected against any of the selected unrelated target 
proteins, indicating high specificity of isolated, semi-synthetic vNAR domains (Fig. 32). However, all 
clones showed promiscuous binding to human and also murine EpCAM, an attribute which may be 
useful for animal studies.  
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Figure 32. Specificity of α-EpCAM vNAR H3 (A), H5 (B) and 5005 (C) as determined via binding assays on the yeast 
surface. Off-target binding was validated against unrelated target proteins tGFP, murine EGFR (mm) and recombinant 
human EphA2. Target binding was verified against recombinant human (rh) EpCAM and murine (mm) EpCAM. cMyc 
normalized antigen binding is shown. Grey: negative control (cells stained for cMyc surface display and with Penta-His 
Alexa Fluor 488 conjugate). Black: target/off-target binding against 1 µM of the respective antigen (incubation time with 
target: approx. 30 min; 2
nd
 staining-step with Penta-His Alexa Fluor 488 conjugate). 
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5.7.4 Tumor cell staining assays 
To examine whether α-EpCAM-vNAR 5005 Fc-fusion protein can be used to selectively target 
EpCAM positive cells, tumor cell staining assays were conducted (4.6.3). In this study, four different 
cell lines were used, MCF-7, EBC-1(personal communication Achim Doerner, Merck Serono 
Darmstadt) and T47D, considered as EpCAM positive cell lines as well as CHO(s) cells, generally 
recognized as EpCAM negative.[190-194] 
For this purpose, analysis of cell binding was performed by FACS analysis. Approximately 5 x 10
5 
cells of the respective cell line were centrifuged and used for each antibody and vNAR staining. As 
positive control, EpCAM-specific antibody clone HEA-125 conjugated to PE was used in a dilution of 
1:11, according to the manufacturer’s instructions (MACS, Miltenyi Biotec). Cells were stained for 
approximately 1 hour at 4 °C with α-EpCAM-vNAR 5005 Fc fusion protein in different concentrations 
or with the control antibody. After washing and incubation with anti-human IgG conjugated to PE 
(Fcγ-specific, eBioscience), except for EpCAM-specific antibody HEA-125, cells were analyzed.  
As shown in Figure 33, the vNAR-Fc fusion bound significantly to all EpCAM positive cell lines 
(Fig. 33). However, strongest binding was observed for CHO cells, whereas the positive control, 
EpCAM-specific clone HEA-125 did not show any binding, giving clear evidence for strong off-target 
binding in a concentration-dependent manner. Hence, it was unfeasible to use α-EpCAM-vNAR 5005 
for in vivo studies such as tumor xenograft models. 
This observation had several consequences for the follow-up project which was the construction of a 
vNAR domain, simultaneously targeting two different antigens. For this engineering approach, vNAR 
5005 was used as starting molecule, because at the time this particular project was started, evidence for 
unspecific binding of this antibody domain was missing. Due to the unfeasibility of the utilization of a 
bi-specific molecule based on vNAR 5005 for cell assays as well as in vivo studies, bi-specificity of 
engineered vNAR domains could only be validated using different methodologies of in vitro 
characterization.   
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Figure 33. Specificity of α-EpCAM vNAR 5005 Fc fusion protein validated by tumor cell staining assays. Different cell-
lines are shown. Cells were incubated with vNAR Fc fusion protein or EpCAM-specific control antibody for approx. 1 h, 
washed and incubated with Fc-specific secondary antibody-PE conjugate (except for control antibody). Grey: Cells labeled 
with Fc-specific secondary antibody-PE conjugate only. Black: Cells labeled with EpCAM-specific control antibody. 
Blue: Cells labeled with 1 µM α-EpCAM vNAR 5005 Fc fusion protein. Red: Cells labeled with 0.5 µM α-EpCAM vNAR 
5005 Fc fusion protein. 
 
 
5.8 Generation of a new paratope into the vNAR scaffold through randomization 
of HV2 
The following chapter describes the generation of a new antigen-binding site into HV2 of the vNAR 
domain. Through the randomization of this surface-exposed loop and library screening, binders were 
isolated with the capability to target distinct antigens with HV2. Hence, HV2 was used to engineer a 
second paratope that acts independently from the conventional antigen-binding site, composed of 
CDR3 and CDR1 (and potentially HV4). Importantly, as validated using yeast surface display, the 
establishment of this new and unique feature did not impair the conventional paratope’s affinity for its 
target, clearly indicating the structural integrity of the vNAR domain. The rationale for this was that 
for vNAR type II and type IV, HV2 is located distantly from the conventional paratope (Fig. 34). Note 
that crystallography revealed that for type I vNAR domains, CDR3 is located in close proximity to 
HV2.[24] It was shown that HV2 is prone to mutations [98], accordingly, we believed that the vNAR 
overall structure tolerates mutations in this region without largely compromising its structural 
integrity. Therefore, α-EpCAM-vNAR 5005 was used as starting molecule, which targets EpCAM 
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with CDR3 and CDR1. Through the diversification of HV2, we wanted to select for binders targeting a 
new antigen with HV2 whilst retaining its ability to target EpCAM. 
 
Figure 34. Depiction of the rationale for the generation of a new antigen-binding site into the vNAR scaffold. The 
conventional paratope composed of CDR3, CDR1 (and HV4) is shown in red. The potentially new antigen-binding site, 
consisting of HV2 is shown in blue. Yellow: Disulfide bond. Model based on pdb entry 4HGK [103] generated using 
YASARA structure.[107] Sequence shown for parental molecule 5005 used for library design. Sequence for CDR1 and 
CDR3 as well as HV4 of the conventional antigen-binding site shaded in red. Residues in sequence exposed loop 
corresponding to HV2 and considered for randomization shown in blue. Figure was constructed in close cooperation with 
Martin Empting. 
 
5.8.1 Construction of a HV2 randomized library based on EpCAM-specific vNAR 5005 
For the generation of a HV2 randomized library based on EpCAM-specific vNAR 5005, the pCT 
plasmid, isolated from the respective single clone was used as starting material (4.2.3). Akin to 
randomization of CDR3 and CDR1, diversifications were performed by incorporation of triplet codons 
into the corresponding oligonucleotide. Nine residues of the surface-exposed loop HV2 were chosen 
for randomization. Library was established in a consecutive two-step splicing by overlap extension 
PCR, as schematically depicted in Figure 35 (Fig. 35). For the first PCR step, two reactions were 
carried out in parallel. On the one hand, primer pair HV2_SOE_rand_up/pCT_Seq_lo was used to 
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randomize nine residues within HV2. pCT_Seq_lo hybridized at the plasmid backbone, to conserve 
CDR3 as well as framework region 4. On the other hand, to generate the corresponding low vNAR 
fragment, primer pair pCT_Seq_up/HV2_SOE_lo was employed. Afterwards, 1 µl of PCR-products 
were used as template for the follow-up second PCR reaction, respectively. After six cycles, primer 
pair pCT_Seq_up/pCT_Seq_lo was added to generate the complete HV2-randomized vNAR fragment 
with sites for homologous recombination in S. cerevisiae. 
 
Figure 35. Schematic representation of PCR-based randomization of HV2. pCT plasmid encoding EpCAM-specific 
vNAR 5005 was used as template. In first PCRs HV2 was randomized and the corresponding up and low fragments of the 
vNAR domain were constructed. In a subsequent reaction the total vNAR molecule was constructed via splicing by 
overlap extension.  
 
A yeast surface display library was established akin to initial library construction, as described in 
chapter 5.2. This yielded in a library diversity of approximately 10
9
 unique clones as determined by 
dilution plating.  
Library quality was assessed using yeast surface display with regard to cMyc-labeling (4.3.1) and 
EpCAM-labeling (4.3.2, Fig. 36). Within one day post-induction, there was approximately 40 % of 
cMyc-labeling, giving evidence for expression and high copy number display of HV2-diversified 
vNAR domains on the surface of S. cerevisiae. Moreover, we were able to detect about 36 % of 
EpCAM-binding, indicating that the vast majority of displayed vNARs, which are progenies of 
α-EpCAM-vNAR 5005, retain their structural and functional integrity. 
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Figure 36. Analysis of HV2-randomized library based on EpCAM-specific vNAR 5005. Histogram of cMyc surface 
expression (left) and EpCAM binding (1 µM EpCAM, right) of the constructed vNAR library assessed by indirect 
immunofluorescence labeling and flow cytometry one day post induction. Cells in gate: 40.1 % for cMyc staining and 
35.9 % for EpCAM-labeling (detected with EpCAM-specific antibody clone HEA-125 conjugated to PE). 
 
5.8.2 Selection of vNAR molecules targeting CD3ε 
Recombinant human cluster of differentiation 3 subunit ε (CD3ε) was purchased from 
AcroBiosystems.  It consists of amino acids Asp23-Asp126 fused to a hexa-histidine tag for detection. 
The calculated molecular weight is predicted to be 13.2 kDa. 
To isolate single clones, that bind CD3ε while retaining high affinity for EpCAM, the first round of 
screening was performed two-dimensionally for target binding, using his-tagged EpCAM and 
biotinylated CD3ε (4.3.4). Hence, antigen binding was detected using Alexa Fluor 488 labeled anti-
His-tag antibody as well as streptavidin-APC. In the first round of screening, approximately 2 x 10
8
 
clones were sorted (Fig. 37). In the second and third round, cells were only sorted for CD3ε-binding, 
since cMyc surface labeling was around 50 %. To avoid off-target binding against detection reagents, 
the labeling strategy was alternated from using biotinylated CD3ε to his-tagged antigen which was 
detected via Alexa Fluor 488 labeled anti-His-tag antibody. Moreover, the target concentration was 
reduced in the third screening round to enhance stringency. For this reason and also due to the 
presence of a minor target-positive population, a resort was performed after round three. The fourth 
round of sorting revealed a significant enrichment of a double target-positive population. Peculiarly, as 
shown in Figure 37, also only CD3ε-positive clones were enriched. However, since we were only 
interested in bi-specific clones, we exclusively selected for EpCAM- and CD3ε-positive populations 
(Fig. 37).  
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Figure 37. Screening of a HV2-randomized EpCAM-specific library based on vNAR 5005 against CD3ε. Sorting gates and 
target concentrations are shown. In round one and four, cells were simultaneously labeled for EpCAM binding using Penta-
His Alexa Fluor 488 conjugate and CD3ε binding via biotinylated antigen and Steptavidin-APC. In round two and three, 
cells were only labeled for CD3ε binding using his-tagged antigen and Penta-His Alexa Fluor 488 conjugate. After round 3 
a resort was performed. Cells in the sorting gate were isolated, grown and induced for the next round of selection. Target-
positive cells in sorting gate: (R1) 0.1 %; (R2) 0.17 %; (R3) 1.92 % and (R4) 5.8 %. 
 
Single clones were analyzed in terms of their ability to target both antigens (4.3.2). As shown for 
clones αEpCAM-CD3ε-vNAR H5 and αEpCAM-CD3ε-vNAR B1 in Figure 38, several double-
positive clones were identified, whereas for the parental molecule α-EpCAM- vNAR 5005 no binding 
was observed against CD3ε (Fig. 40). Most of the clones still bound strongly to EpCAM at a 
concentration of 1 µM, but binding to CD3ε was very weak at 1 µM, as exemplarily shown for single 
clone αEpCAM-CD3ε-vNAR H5. Notwithstanding, for one clone, referred to as 
αEpCAM-CD3ε-vNAR B1 we observed binding to CD3ε to a significantly higher extent compared to 
all other analyzed clones. However, binding to EpCAM was only moderate, indicating that in this 
particular case the randomized HV2 sequence impairs EpCAM-binding at the conventional antigen-
binding site. Sequencing of double positive clones revealed several different, potentially bi-specific 
vNARs (Fig. 39). Since all but one single clone only showed very weak binding to CD3ε, we decided 
only to characterize αEpCAM-CD3ε-vNAR B1 in more detail.  
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Figure 38. Single clone analysis of potentially bi-specific vNARs after randomization of HV2 and library screening for 
EpCAM and CD3ε binding. Single clones were incubated with 1 µM of the respective antigen. Alexa Fluor 488 labeled 
anti-His-tag antibody was used for the detection of target binding. Blue: Cells stained with EpCAM. Black: Cells incubated 
with CD3ε. Grey: Negative control, cells only labeled with secondary detection antibody. 
 
Affinities of the potentially bi-specific clone α-EpCAM-CD3ε-vNAR B1 as well as its parental clone 
α-EpCAM-vNAR 5005 were assessed via affinity titration on the yeast surface (4.3.3, Tab. 5). 
α-EpCAM-CD3ε-vNAR B1 showed an affinity for CD3ε of about 409 nM. However, the affinity 
against EpCAM, declined substantially compared to the parental clone. As shown in Figure 39, bi-
specific clone α-EpCAM-CD3ε-vNAR B1 bears an Arg56Gln mutation at the interface between the 
surface-exposed loop corresponding to HV2 and the adjacent framework region, referred to as 
framework region 3a (Fw3a). Importantly, this residue was not considered for library design.  
 
Table 5. Equilibrium dissociation constants (KD) determined by yeast surface display for bi-specific HV-randomized 
clones compared to the parental clone. 
vNAR 
clone 
Type of molecule KD [nM] 
EpCAM 
KD [nM]  
CD3ε/Fcγ 
5005 Parental molecule 40 ± 13 - (CD3ε/ Fcγ) 
B1 After library screen (Gly-Gln-Tyr motif) CD3ε ~ 1500 409 ± 70 (CD3ε) 
B1mut Q  R framework (Gly-Arg-Tyr motif) CD3ε 46 ± 8 422 ± 60 (CD3ε) 
F1 After library screen human Fcγ 53 ± 10 ~ 2600 (Fcγ) 
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Sequence comparison of different vNAR types and also of different shark species revealed a conserved 
Gly-Arg-Tyr motif (Gly55 – Tyr57) at the interface between HV2 and Fw3a (Appendix B). To 
determine whether the mutated Gly-Gln-Tyr motif has a negative impact on EpCAM-binding for bi-
specific clone B1, we employed a backward mutation (Gly-Gln-Tyr to Gly-Arg-Tyr) via SOE-PCR 
(4.2.3). The PCR product was established in a consecutive two-step PCR, akin to HV2-randomization 
(Fig. 31). For the first PCR step, two reactions were carried out in parallel. On the one hand, primer 
pair HV2_B1mut_up/pCT_Seq_lo was used to reincorporate the Arg residue at the desired position. 
On the other hand, to generate the corresponding low vNAR fragment, primer pair pCT_Seq_up/ 
HV2_B1mut_lo was used. Afterwards, 1 µl of PCR-products were used as template for the follow-up 
second PCR reaction, respectively. After six cycles, primer pair pCT_Seq_up/pCT_Seq_lo was added 
to generate the complete mutated vNAR B1mut fragment with sites for homologous recombination in 
S. cerevisiae. EBY 100 cells were transformed with the described PCR product and with pCT plasmid. 
 
Figure 39. Sequences of potentially bi-specific EpCAM binding and CD3ε binding vNARs aligned to parental mono-
specific molecule 5005. Dots indicate identical residues. Blue: Residues in surface-exposed loop corresponding to HV2 
considered for library design. Red: Residue at the interface of HV2 and FW3a not considered for library design. 
 
EpCAM-binding and binding to CD3ε was evaluated on the yeast surface using 1 µM of target (4.3.2), 
respectively, and compared to the parental molecule 5005 (Fig. 40). Equilibrium dissociation constant 
titration (4.3.3) confirmed the observation, that affinity for EpCAM was restored through the backward 
mutation to the original framework (Gly-Arg-Tyr motif), that is conserved amongst shark species as 
well as vNAR types (Tab. 5). Importantly, conversion into the original framework did not 
significantly influence the affinity for CD3ε. Essentially, these findings are giving clear evidence that 
bi-specific vNAR molecules can be generated using this novel approach in which HV2 facilitates 
antigen binding. 
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Figure 40. Single clone analysis of mono-specific, parental clone 5005 and HV2-diversified clone B1 for EpCAM and 
CD3ε binding. Single clones were incubated with 1 µM of the respective antigen. Alexa Fluor 488 labeled anti-His-tag 
antibody was used for the detection of target binding. Blue: Cells stained with EpCAM. Black: Cells incubated with CD3ε. 
Grey: Negative control, cells only labeled with secondary detection antibody. 
 
5.8.3 Selection of vNAR molecules targeting Fcγ 
In order to study whether this new strategy for the generation of a new antigen-binding site into the 
vNAR scaffold is generally applicable, the same library was also screened to select for binders, 
simultaneously addressing EpCAM and human Fcγ. For this, a non-glycosylated IL8-vNAR-Fcγ 
fusion protein (made in-house) was used as target protein.  
In the first round of sorting approximately 2 x 10
8
 cells were screened (4.3.4, Fig. 41). Binding to 
EpCAM was detected using Alexa Fluor 488 labeled anti-His-tag antibody and binding to Fcγ was 
detected using anti-human IgG conjugated to PE (Fcγ-specific, eBioscience). To avoid off-target 
binding against detection reagents, the second and third round of sorting was carried out only one-
dimensionally. In the second round of screening, Fcγ-binding was detected via a Fcγ-specific Fab-
fragment conjugated to Alexa Fluor 488. In the third round of sorting this secondary detection reagent 
was once again alternated to anti-human IgG PE-conjugate. In this round, a significant enrichment of 
target-positive populations was detected. To isolate binders that target both, EpCAM and human Fcγ, 
in the fourth round, sorting was once again switched to two-dimensionally screening for simultaneous 
detection of bi-specific target binding. 
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Figure 41. Screening of a HV2-randomized EpCAM-specific library for bi-specificity against human Fcγ. Sorting gates 
and target concentrations are shown. In round one and four, cells were simultaneously labeled for EpCAM- and Fcγ-
binding. In round two and three, cells were only labeled for Fcγ-binding. Cells in the sorting gate were isolated, grown and 
induced for the next round of selection. Target-positive cells after sorting gate: (R1) 0.11 %; (R2) 0.41 %; (R3) 14.68 %   
and (R4) 9.21 %. 
 
Single clones were analyzed for bi-specificity (4.3.2) and double-positive clones were sent out for 
sequencing, resulting in only one single sequence (Fig. 42). Characterization of this clone (4.3.3), 
referred to as α-EpCAM-Fcγ-vNAR F1, resulted in a low affinity against human Fcγ of approximately 
2.6 µM without significantly compromising the affinity against EpCAM compared to its parental clone 
5005, as listed in Table 5 (Tab. 5). Of note, parental molecule 5005 does not display any affinity for 
human Fcγ. Interestingly, clone F1 only bound to non-glycosylated human Fcγ, as investigated with 
solitary Fc-fragments (provided by Stephan Dickgießer, Technische Universität Darmstadt). For the 
glycosylated equivalent we were unable to detect any binding at the highest concentrations tested 
(Fig. 43). Hence, one can draw conclusions with regard to the epitope that is addressed by 
α-EpCAM-Fcγ-vNAR F1. It is tempting to speculate, that position 297 of Fcγ is involved in the 
vNAR-target-interaction, since for wild-type Fcγ, this residue is Asn which is typically glycosylated. 
However, the provided unglycosylated Fcγ contains an Asn to Ala mutation at this position and it can 
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be assumed that this mutation, that prevents glycosylation, is part of the epitope targeted by 
α-EpCAM-Fcγ-vNAR F1. Another hypothesis is that glycosylation of the Fc-fragment covers the 
epitope targeted by α-EpCAM-Fcγ-vNAR F1 in a way that this region as structurally not accessible.  
 
Figure 42. Sequences of bi-specific EpCAM binding and Fcγ binding vNAR F1 aligned to parental mono-specific 
molecule 5005. Dots indicate identical residues. Blue: Residues in surface-exposed loop corresponding to HV2 considered 
for library design 
 
 
Figure 43. Single clone analysis of EpCAM and glycosylated Fcγ binding bi-specific clone F1. Single clone was incubated 
with 1 µM of the respective antigen. Anti-human IgG conjugated to PE (Fcγ-specific, eBioscience) was used for the 
detection of target binding. Grey: Negative control, cells only labeled with secondary detection antibody. Black: Cells 
incubated with glycosylated Fcγ. Red: Cells labeled with non-glycosylated Fcγ. Blue: Cells labeled with EpCAM and 
detected via EpCAM-specific antibody clone HEA-125 conjugated to PE. 
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6. DISCUSSION 
6.1 Library construction, selection of antigen-specific vNAR molecules and affinity 
maturation of enriched target binding variants 
Within the scope of this work we successfully developed an in vitro affinity maturation process for the 
generation of high-affinity vNAR domains using yeast surface display as platform technology. The 
isolation of affinity-matured binders was performed in a two-step process. Screening from a semi-
synthetic vNAR library in which CDR3 was totally randomized resulted in the selection of binders 
comprising moderate affinities to their target, that were improved by diversification of CDR1 and 
sublibrary screening.  
Initially, binders were selected against EpCAM, EphA2, HTRA1[187] and IL-8, clearly demonstrating 
that vNAR molecules can be isolated from this semi-synthetic library to target a wide range of 
different antigens. Affinity maturation was employed for EpCAM, HTRA1,[187] and IL-8 binding 
vNAR domains, giving evidence, that this new methodology is generally applicable. Additionally, a 
subset of binders was produced as soluble proteins in E. coli and in vitro characterization using 
biolayer interferometry confirmed the affinity maturation process and affinities as determined on the 
yeast surface. 
Deep sequencing of natural bamboo shark vNARs from non-immunized animals confirmed that the 
primary vNAR diversity of this species is mainly restricted to CDR3, while the other regions (CDR1, 
HV2 and HV4) demonstrate only minor variations.[109] Expanding the set of variants by generating a 
semi-synthetic library of 2 x 10
8
 variants with fully randomized CDR3 proved to be a valid strategy to 
obtain antigen binding vNAR molecules. In this respect, previous experiments failed to isolate 
EpCAM-specific vNAR molecules from the naїve repertoire of Chiloscyllium plagiosum (not shown). 
Regarding this, it is worthy to mention, that the total number of unique clones in this library was 
comparable to those of the herein presented semi-synthetic library. 
Interestingly, in the original vNAR repertoire of the bamboo shark, typically one cysteine residue in 
CDR1 was conserved that presumably forms a disulfide bond with a Cys residue in CDR3 (Fig. 1C). 
In sharks three different types of vNARs have been characterized based on the position of non-
canonical Cys residues.[51] An additional type of IgNAR, termed type IV, possesses only one 
canonical disulfide bond. Except IgNAR type III, which has limited sequence diversity in CDR3, all 
types give rise to antibodies with high affinities.[100,101,104,106,113,115] The semisynthetic library 
is cysteine-free in CDR3 and also has Cys in CDR1 replaced by Tyr. Therefore, it may be possible that 
the enhanced conformational flexibility of CDR3 compared to the disulfide bond constrained natural 
loop contributes to accommodation of target-protein interaction and allows for the successful isolation 
of a large set of different vNARs, albeit with low affinity to their target.  
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Moreover, we designed the library to be of type IV to obviate protein misfolding due to a potential 
presence of a significant proportion of disulfide patterns which perturb the structural integrity of the 
vNAR domain in a Cys-biased library. However, such semi-synthetic Cys-biased CDR3 randomized 
Type II libraries were constructed by Nuttall and colleagues who isolated vNAR molecules 
specifically targeting Gingipain K protease from Porphyromonas ginglivalis.[106] In contrast to our 
work, this group used phage-display as platform technology and nowadays, the generation of very 
large antibody phage-display libraries with diversities of more than 10
11
 unique clones is 
amenable.[195,196] This significantly exceeds diversities of yeast surface display libraries.[149,181] 
Thus, it can be hypothesized that it is feasible to select binders from such huge phage-display libraries 
that display high affinity and stability, in spite of the presence of potentially misfolded, non-functional 
molecules.  
Nonetheless, it would be interesting to analyze the screening outcome from a vNAR library of similar 
diversity that contains Cys in the randomized CDR3 loop and a potentially disulfide bond-forming Cys 
in CDR1 with respect to structural integrity, clonal diversity of isolated binders and their target 
affinities.  
Such Cys-biased, CDR3-diversified libraries typically give rise to binders with KD values in the 
double-digit to triple-digit nanomolar range.[113] Likewise, it was shown by Goldman and co-
workers, that high-affinity binders can be isolated from a semi-synthetic CDR3 mutagenized vNAR 
library against different antigens [114] that were lacking the inter-loop disulfide bond. In conclusion, 
the inter-loop disulfide bond between CDR1 and CDR3, if present, likely contributes to binding 
affinity and structural stability, but is not absolutely required to obtain high-affinity vNARs. 
Stepwise affinity optimization by first randomizing CDR3 and accumulating a set of low affinity 
binders followed by diversification of CDR1 in this population of enriched variants proved a useful 
strategy to obtain vNARs with affinities in the low nanomolar range. As described by Wittrup and 
colleagues, library establishment in S. cerevisiae and screenable throughput limit the number of clones 
that can be analyzed in a combinatorial library.[156,197] As a consequence, we decided to perform 
this consecutive enrichment and affinity maturation procedure, to decline the theoretical sequence 
space in an ideally unbiased library for a more comprehensive library sampling. A simultaneous 
randomization of twelve residues within CDR3 and five residues in CDR1 would comprise a 
theoretical sequence diversity of approximately 5.5 x 10
21
, whereas a consecutive diversification of 
twelve residues followed by randomizing five residues of drastically reduced target-enriched 
sequences decreases the theoretical sequence space to about 2 x 10
15 
and 2.5 x 10
6
 (the latter projected 
for the affinity maturation of one binder), respectively. It needs to be mentioned that even in a library 
of 2 x 10
8 
unique clones, theoretical sequence space is greatly undersampled. In contrast to the 
simultaneous randomization of the CDRs of the vNAR domain, this stepwise selection and 
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optimization technique leastwise ensures appropriate sampling of the respective sublibrary for affinity 
maturation that enables the analysis of every single variant in terms of enhancing affinity. 
Interestingly, this novel in vitro affinity maturation method also resembles the natural strategy of the 
immune system of nurse sharks [109] to select clones from a primary IgNAR repertoire that is nearly 
entirely CDR3-based, followed by affinity maturation of complementarity determining regions and 
hypervariable loops after antigen exposure, with a significant bias towards replacement substitutions in 
CDR1.[98] The stepwise screening strategy is similar to the isolation of camelized human VH domains 
by phage display, where low-affinity binders were selected from a CDR3 randomized VH domain. 
Subsequent diversification of CDR1 or CDR2 residues provoked a significant increase in affinity 
[198,199]. While in these studies a single VH scaffold was chosen for CDR randomization, we used a 
repertoire of natural scaffold molecules from non-immunized animals. This may contribute to the 
successful isolation of a large set of stable binders, since small variations in the scaffold sequence are 
known to have a large impact on folding stability and protein solubility [200,201]. 
Although affinity matured EpCAM-binders selected with this method comprised low nanomolar 
affinities similar to those obtained from nurse sharks immunized with hen egg lysozyme [100], none of 
the selected binders showed sub-nanomolar affinities, that were recently obtained by immunization of 
Squalus acanthias with human serum albumin [101]. Nevertheless, subsequent third-round 
randomization of HV4 that potentially contributes to the paratope may result in variants with further 
enhanced affinities.  
Since the development of yeast surface display, pioneered by Boder and Wittrup in 1997, it was 
extensively shown that this cellular display technology can be successfully utilized to engineer 
antibody-like molecules and also a wide range of alternative binding scaffolds [69,146,150,202-205]. 
As already discussed, one of the major benefits of this display method is control over the selection 
process, as it harbors the potential of single cell real-time and on-line analysis and subsequent 
characterization of individual library candidates. Another beneficial attribute is the possibility to co-
select for high-level expression and stability simultaneously to the binding functionality [146,149]. 
Moreover, proteins are believed to be most likely well-folded since quality control machineries exist in 
S. cerevisiae for proper protein folding [206]. In addition, isolated binders can be instantaneously 
characterized in terms of affinity and specificity without the need for soluble expression [146,182]. 
Finally, sampling of libraries supposedly is more comprehensive with yeast display than with phage 
display [157]. This might be particularly important for the selection of rare binders from large library 
e.g. naїve or artificial repertoires. Yet, it needs to be mentioned, that this drawback of library sampling 
is at least partially compensated for phage display libraries due to the feasibility of constructing 
libraries with larger clone numbers.[195,196] Ultimately, this study adds vNAR antibody domains to 
the growing list of scaffold molecules that can be easily isolated, characterized and optimized using 
this powerful display technology. 
   
-87-  
 
A set of EpCAM-specific vNAR molecules was produced in E. coli as soluble protein. Though, 
expression yields were only moderate to low, ranging from 0.3 mg/L to 1.1 mg/L. In contrast to these 
findings, Nuttall and co-workers reported about vNAR yields ranging from 3 mg/L to 5 mg/L for 
expression into the E. coli periplasm.[119,125] Unlike Nuttall et al., we expressed the vNAR domain 
as fusion protein. Consequently, two purification procedures as well as one additional manipulation 
step (TEV-cleavage) were performed to isolate the respective soluble domain. It can be suggested that 
the low expression yields are at least partially based on these multifactorial purification and 
manipulation procedures. It is the author’s opinion, that this inherent limitation of expression yields 
may be optimized by obviating the production of selected vNAR molecules as fusion protein in E. coli. 
In this respect, soluble expression of the solitary vNAR domain would substantially decrease 
manipulation steps needed for purification and it can be concluded that this would significantly 
enhance expression yields.  
To enhance vNAR expression, affinity-optimized α-EpCAM-vNAR 5005 was genetically fused to the 
N-terminus of a human Fc domain. The rationale was that fusions to the human Fc-part, besides 
enhancing vNAR expression yields, also lead to the formation of dimers. This attribute might be 
advantageous in terms of enhancing functional affinity i.e. avidity.  Moreover, for cell-based staining 
assays, binding of Fc-fusion proteins to cells e.g. tumor cells can easily be detected using fluorescence-
labeled secondary antibodies targeting the human Fc-part. Expression yields for α-EpCAM-vNAR 
5005 Fc-fusion protein extensively exceeded those for production in E. coli. Thus far, the expression 
level of approximately 192 mg/L is to the best of our knowledge the highest reported expression yield 
for vNAR fusions. Typically vNARs are expressed as Fc fusion protein at levels varying from 10-
40 mg/L.[103] 
The superior thermal stability compared to ScFv- and mAb-formats is a hallmark of vNAR 
domains.[104,121] Taking a closer look in order to verify whether this is also in accordance with semi-
synthetic type IV domains originating from the bamboo sharks’ antibody repertoire, thermal shift 
assays were executed to determine the melting temperature. All three analyzed vNAR fragments 
exhibited high thermal stability of approximately 75 °C, 71.5 °C and 65 °C, respectively. Interestingly, 
affinity-optimized EpCAM-specific vNAR possessed the lowest Tm, which constitutes a significant 
loss of stability compared to its parental molecule H3 (Tm of ~ 75 °C). Thus, in this particular case 
enhancement of affinity is at the cost of thermal stability. As repeatedly mentioned, the primary 
repertoire of sharks is nearly exclusively CDR3-based. In conclusion, CDR1 is conserved in the 
IgNAR gene cluster.[24,99] Consequently, it is tempting to speculate that during evolution a very 
thermo-stable framework evolved and that it can be expected that mutations in CDR1, whilst 
increasing the affinity for antigen binding, might have a negative impact in terms of stability. 
Nevertheless, we could prove that even semi-synthetic type IV vNAR domains, which lack any non-
canonical loop stabilizing disulfide bonds, show superior thermal stability compared to mammalian 
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antibody domains. Related to the latter, scFv fragments for instance, often show Tm values in the 
range between 50 °C and 65 °C.[207,208] However, Tm values for scFvs may sometimes fall below 
40°C requiring optimization of thermal stability.[209]  
As extensively reviewed, equilibrium dissociation constants measured through titration on the yeast 
surface are consistent with affinities determined using purified and soluble protein.[146,210,211] To 
examine, whether this is also consistent with vNAR domains isolated and characterized by yeast 
surface display, we determined affinities of EpCAM-specific vNARs from initial screening 
experiments and after affinity maturation via biolayer interferometry. Essentially, affinities for vNARs 
as measured on the yeast surface correlated well with dissociation constants, assessed with soluble, 
solitary vNAR domains. For all of the analyzed proteins the deviance between both analysis methods 
was less than the factor of three. This concordance is a valuable attribute for the generation of hit 
candidates from shark vNAR libraries using yeast surface display as platform technology, since there 
is no need for soluble expression and purification of individual clones in order to rank affinities of 
clones isolated against a given target. As also demonstrated, formatting of α-EpCAM-vNAR_5005 
into the Fc-format did not impair affinities against EpCAM. Whereas we only detected a slight 
increase in on-rate kinetics, off-rate kinetics were significantly improved, resulting in a moderate gain 
of affinity, indicating a benefit due to functional affinity effects. This data suggests that vNAR 
domains can be engineered into the Fc-framework, without any loss of function. 
Of additional concern was selectivity of isolated vNARs. For this, specificity assays were employed on 
the yeast surface with different unrelated target proteins for a subset of EpCAM-specific vNARs. For 
all tested unrelated proteins, no significant off-target binding was observed. Furthermore, for affinity-
optimized α-EpCAM-vNAR_5005 we could show that there also was no unspecific binding against 
CD3ε and unglycosylated human Fcγ protein detectable. Contradictory to this, we observed extensive 
off-target binding of this vNAR variant against EpCAM-negative cell line CHO in cellular 
immunofluorescence assays. Conspicuously, intensities of binding for this EpCAM-negative cell line 
exceeded intensities for EpCAM-positive cell lines, MCF-7, EBC-1 and T47D, respectively, to a large 
extent. Hence, this data suggests rather specific off-target binding to a molecule of unknown nature 
displayed on the membrane of CHO, than unspecific off-target binding. Off-target binding is a major 
concern for in vitro and de novo generation of antibody-molecules against a given target, owing to the 
lack of any immune surveillance i.e. in vivo selection and regulatory mechanisms. In contrast to this, 
host-generated antibodies i.e. respective antibody-producing B-cells, cross-reacting to self-antigens or 
normal tissue are usually eliminated to prevent autoimmune disease.[212] Off-target binding can have 
a negative impact related to pharmacokinetics, tissue distribution, efficacy and toxicity. For instance, 
for adalimumab, which was generated in vitro from a cloned human antibody phage display library, 
multiple off-target interactions were found.[212,213] Importantly, it is hypothesized that serious 
adverse events having an autoimmune etiology can be explained by off-target activities of biologic 
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drugs owing to a disturbed immune balance.[213] A very elegant way to reduce off-target activities 
was described by Kiener and co-workers, who observed unspecific broad tissue binding during the 
humanization and affinity maturation process of motavizumab.[214] They identified three amino acid 
residues, introduced during affinity maturation that mainly mediated non-specific tissue binding. The 
reversion of those three residues back to the original sequence led to a reduction in off-target binding 
and improved overall efficacy in vivo. With this in mind, it can be concluded that there are important 
challenges that emerge beyond basic antibody-antigen binding and it seems that some of them may 
especially affect in vitro generated antibodies that suffer from the lack of regulatory immune 
surveillance. 
Nevertheless, owing to specificity of affinity optimized α-EpCAM-vNAR_5005 with selected proteins 
in vitro, this antibody domain proved to be appropriate for further continuing proof-of-concept studies 
such as the generation of bi-specific vNAR molecules, where a single vNAR antibody domain 
simultaneously targets two different antigens, as described in the scope of this thesis. 
 
6.2 Generation of a new antigen-binding site into the vNAR scaffold through 
diversification of hypervariable loop 2  
Within this work, we generated a new antigen-binding site into the vNAR scaffold, solely facilitating 
antigen binding. Diversification of nine residues within the surface-exposed loop corresponding to 
hypervariable loop 2 combined with library screening using yeast surface display proved to be a valid 
strategy for the identification of bi-specific IgNAR V domains targeting two distinct antigens. Hence, 
we demonstrated that HV2 of the vNAR domain can be functionalized to form an autonomous antigen-
binding site, independent from the conventional paratope, consisting of CDR3 and CDR1 (and 
potentially HV4). 
For this, we chose to use well-characterized EpCAM-binding vNAR 5005 as scaffold for 
randomization. As aforementioned, this antibody domain binds to EpCAM with high affinity. 
Additionally, selectivity assays against unrelated target proteins demonstrated no unspecific binding 
against unrelated target proteins and more importantly, also no off-target binding was observed against 
CD3ε and non-glycosylated human Fcγ. We successfully showed, that through diversification of HV2, 
binders can be selected against two proof-of-concept antigens. Isolated and characterized clones 
comprised moderate affinities for their target, while retaining high affinity against EpCAM. 
The surface-exposed loop, comprising hypervariable loop 2 is considerably longer (Lys43 – Arg56) 
than the nine residues, considered for library design (Ala45 – Thr 53). However, sequence comparison 
between different vNAR types across different species revealed a conserved Gly-Arg-Tyr motif at the 
end of this surface-exposed loop (Gly55 – Tyr57), as depicted in Appendix B. Consequently, these 
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residues were excluded for library design. Interestingly, CD3ε and EpCAM binding molecule B1 
contained an Arg56Gln mutation. Peculiarly, this residue was not considered for library design. This 
molecule displayed moderate affinities against CD3ε, yet, affinities against EpCAM were substantially 
diminished compared to parental molecule 5005, giving clear evidence that the conserved Gly-Arg-Tyr 
motif is crucial for the structural integrity of the vNAR scaffold. In this respect, we were able to show 
that transformation into the original Gly-Arg-Tyr motif entirely restored affinities towards EpCAM 
without any loss of function against CD3ε. 
Characterization of the established library by FACS analysis for staining with EpCAM showed that the 
vast majority of displayed clones (~ 89.5 %) retained high affinity for the original antigen, indicating 
that a large portion of library candidates tolerated well the modification of this structural loop. Related 
to this, isolated bi-specific vNAR clones did not display any significant loss of affinity against 
EpCAM, demonstrating the versatility of this new strategy.  
It is generally known, that the immunoglobulin family evolved a paramount tolerability in loop length 
as well as sequence variation, which is most evident for CDR regions of variable domains. However, 
this feature is a general hallmark of the immunoglobulin domains.[69,215] In this respect, surface-
exposed loops at the N-terminal tip of CH2 of human IgG have been engineered for antigen 
binding.[216] In another very elegant approach, established by Rüker and co-workers, a new antigen-
binding site was introduced into C-terminal loop regions of the CH3 domain of human IgG.[69] Most 
importantly, those engineered Fc fragments, named Fcab, retained the ability to elicit effector 
functions, clearly indicating the structural integrity of the molecule. This study adds the vNAR domain 
to the growing class of immunoglobulin scaffold proteins that can be manipulated and tailor-made in 
terms of establishing a new antigen-binding site.  
Although this new methodology allows for the identification and isolation of binders comprising a new 
antigen-binding site, hence, for bi-specific molecules, affinities of the new HV2-facilitated paratope 
against their target proteins were only moderate. Notwithstanding, there might be several 
methodologies applicable to optimize affinities. One could think of randomizing residues Lys43 and 
Gly44 of HV2 to expand the created antigen-binding loop which may contribute to an enhanced 
affinity i.e. to affinity maturation. Another possibility might be to identify residues of HV2 not 
involved in antigen binding via alanine-scanning. After identification, those residues could be 
diversified in a second generation randomization step and a sublibrary could be established. Screening 
with significantly decreased target concentration, as performed in the aforementioned affinity 
maturation process of the conventional antigen-binding site, i.e. randomization of CDR1, might pave 
the way for the identification and isolation of bi-specific vNAR molecules with significantly enhanced 
affinities. Finally, randomization of the adjacent loop of HV2 (Asp74 – Ser80) would substantially 
elongate the surface of a potentially antigen-binding site, drastically increasing the chance to isolate 
high-affinity binders, which would be progenies of HV2-randomized antigen binding, bi-specific 
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clones. Accordingly, this antigen-binding site would comprise two surface-exposed loops, akin to the 
conventional paratope of EpCAM-binding high-affinity vNAR 5005, consisting of CDR3 and CDR1. 
Such antigen-binding sites were constructed into domain CH3 of the human Fc-fragment of IgG, as 
described by Rüker and colleagues.[69] The group randomized the AB and EF loop at the C-terminal 
tip of CH3 and screened for antigen binding Fc fragments using yeast surface display. With this 
strategy, comprising a two-looped paratope, they were able to isolate Fc fragments targeting 
HER2/neu with affinities of 69 nM. Interestingly, also insertions into the surface-exposed loops 
considered for library design did not interfere with the overall structural and functional characteristics 
of the Fc-part. As a consequence, one could also take insertions of randomized residues into HV2 into 
account to elongate the respective loop, for the enhancement of affinities.  
Essentially, this study demonstrates that the vNAR scaffold can be engineered in a way that HV2 
functions as an independent paratope, solely facilitating antigen binding against a target protein. 
Importantly, the establishment of a new paratope does not impair the conventional antigen-binding 
site, composed of CDR3 and CDR1 in its affinity, resulting in a bi-specfifc molecule.   
In further studies, taking a closer look to bi-specificity might be worth to consider. In this respect, 
vNAR molecules need to be expressed as soluble proteins and characterized more meticulously via 
biolayer interferometry to investigate whether the vNAR molecule is capable of targeting both 
antigens simultaneously. Although HV2 of the IgNAR V domain is situated in relative distance to the 
conventional paratope, with the data presented herein, it cannot be excluded that both antigen-binding 
sites compete for antigen binding to their respective target proteins, which would prevent simultaneous 
targeting.   
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8. APPENDIX 
Appendix A. Negative control of screening round 4 against receptor tyrosine kinase 
EphA2 
                                           
Appendix A. Negative control of Library screening round 4 against EphA2. Yeast cells were labeled for simultaneous 
detection of surface presentation and for detection of binding against Alexa Fluor 488 labeled anti-His-tag antibody. 
 
Appendix B. Multiple sequence alignment of vNAR molecules of different types 
from different species 
 
Appendix B. Multiple sequence alignment (CLUSTAL W, v1.83) of different vNAR protein sequences indicating highly 
conserved Gly-Arg-Tyr motif at the end of HV2. Sequences of vNAR molecules were randomly chosen. CDR1, HV4 and 
CDR3 are shaded red, respectively. HV2 shaded blue and conserved motif shaded yellow.  
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Appendix C. Affinities (KD) determined by yeast surface display 
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Appendix D. Abbreviations  
ADCC Antibody-dependent cellular cytotoxicity 
AMA1 Malarial apical membrane antigen-1 
APC Allophycocyanin 
BCR B-cell receptor 
BiP Ig-binding protein 
BSA Bovine serum albumin 
bsAb Bi-specific antibody 
CD3ε Cluster of differentiation 3ε 
CDC complement-dependent cytotoxicity 
CDR Complementarity determining region 
CH2, CH3 Constant domain 2,3 of the heavy chain 
CXCL8 Interleukin-8 
DNL Dock and Lock 
Dscam molecule Down syndrome cell adhesion molecule 
EpCAM Epithelial cell adhesion molecule 
EphA2 Receptor tyrosine kinase EphA2 
FACS fluorescence-activated cell sorting 
Fcγ Fc-part of IgG1 
FcRn Neonatal Fc receptor 
FDA US Food and Drug Administration 
FITC Fluorescein isothiocyanate 
FREP Fibrinogen-related protein 
Fw Framework region 
GFC Gel filtration chromatography 
GFP Green fluorescent protein 
HBeAg Hepatitis B e antigen  
HBV Hepatitis B virus 
HCAb Heavy-chain only antibody 
HSA Human serum albumin 
HTRA1 Human serine protease HTRA1 
HV Hypervariable loop 
IgNAR Immunoglobulin New Antigen Receptor 
IgNAR V domain IgNAR variable domain 
IL-8 Interleukin-8  
IMAC Immobilized Metal Ion Affinity Chromatography 
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KD Equilibrium dissociation constant 
koff Dissociation rate 
LRR Leucine-rich repeat 
mAbs  Monoclonal antibodies 
MalE Maltose binding protein 
MHC Major Histocompatibility Complex 
mm murine 
MWCO Molecular weight cut off 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen associated molecular pattern 
PCR Polymerase chain reaction 
PE Phycoerythrin  
PRR Pathogen recognition receptor 
rh Recombinant human 
scFv Single-chain variable fragment 
SDS sodium dodecyl sulfate 
SOE Splicing by overlap extension 
TCR T-cell receptor 
TEV Tabacco etch virus 
Tm Melting temperature 
TNF Tumor necrosis factor 
VH Variable domain of the heavy chain 
VHH Variable domain of a camelid heavy-chain only 
antibody 
VHSV Viral hemorrhagic septicaemia virus 
VL Variable domain of the light chain 
VLR Variable lymphocyte receptors 
vNAR IgNAR variable domain 
YSD Yeast surface display 
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mich für generelle Hilfen bezüglich Klonierungen, Sucrose-Gradienten und vor allem für die aktive 
Durchführung der Deep Sequencing Projekte bedanken, sowie für einige Kaltschalen, die wir uns 
gemeinsam bei unterschiedlichen Social Events und beim Pirate Sattelite Festival 2012 genehmigen 
durften. Barbara Diestelmann danke ich für die Hilfe in vielen organisatorischen Fragen, für das 
Bereitstellen von Laborutensilien sowie für die vielen anregenden Gespräche während 
Zigarettenpausen und für das gemeinsame Verarbeiten nach einer Dokumentation. 
Christina Uth danke ich für die Freundschaft, die sich hier im Arbeitskreis entwickelt hat, für die 
gemeinsamen Projekte während der Dissertation, für die unzähligen Konzertabende, Koch-, Grill- und 
Trinkabende, Tischkickerspiele und für gemeinsame Konferenzbesuche, allem voran die PEGS Europe 
in Wien.  
Thomas Hofmeyer aka Musclemeyer aka Bud Sperkulegger danke ich für die Benchbruderschaft. Die 
Zeit neben dir und Niklas war wirklich legendär. Ich danke Thomas dafür, dass ich ihn nach einigen 
Remis-Partien nun gänzlich in einem hart umkämpften Armdrückduell bezwungen habe. Weiterhin 
danke ich ihm für gemeinsame Wanderungen, für unzählige gemeinsame Pivo, für gemeinsame 
Erlebnisse im Bruce Willis Actionschacht sowie für ein ganz besonders unkonventionelles Fechtduell, 
das ich mein Leben lang nicht vergessen werde.    
Niklas Weber aka Niklafar aka Sicknick danke für die gemeinsame Freundschaft und für die 
Benchbruderschaft. Ich danke dir für die Kooperation im Haiprojekt und die gemeinsamen 
Konferenzbesuche, hier sei nur kurz Berlin zu erwähnen, wobei alle Interna verschwiegen werden 
müssen! Ich danke dir für das Erlebnis im Bruce Willis Actionschacht, für gemeinsame Wanderungen, 
Konzerte, Touren nach Dublin, Hamburg, Prag und bald Lissabon, für unzählige Kochabende und 
dafür, dass du meinen musikalischen Horizont erweitert hast. Ich danke dir für gemeinsame 
Büdchentouren und so vieles mehr, das mir gerade nicht einfällt! 
Ich danke Simon Krah und Christian Schröter für die gemeinsame Zeit in Lissabon, für gemeinsame 
Biere, für das gemeinsame Schreiben des Reviews sowie für diverse Unterstützung während meiner 
Dissertation. Die allerbesten Jungs… 
Bernhard Valldorf danke ich für gemeinsame Biertouren durch Frankfurt, für das Besuchen der 
Vorträge im Georg-Speyer Haus sowie für die gemeinsame Zeit in Lissabon. Was wäre nur Lissabon 
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ohne dich für ein Höllentrip geworden. Mit dir hat es riesig Spaß gemacht, danke für das Babysitten 
während des Flugs und unmittelbar vor meinem Vortrag, danke für das Erkunden der Stadt, dafür dass 
du mich an deinem Bier hast riechen lassen und umgekehrt und für den Besuch in der pinken Straße. 
Weiterhin danke ich dir für die vielen Gespräche bezüglich arbeitsrelevanter Themen. Sagres, slat! 
Stephan Dickgießer danke ich für die Hilfe und das „Anlernen“ in der Zellkultur. Weiterhin danke ich 
ihm dafür, dass er meinen musikalischen Horizont nicht erweitert hat. Durch ihn habe ich gelernt, dass 
es wirklich objektive Kriterien für gute Musik gibt und dass er diese mit Füßen tritt. Gönn dir, Bruder! 
Heiko Fittler danke ich dafür, dass er der Superchamp ist sowie für das gemeinsame Tischfußball 
spielen.     
Julius Grzeschick, Doreen Könning, Sebastian Meister, Kerstin Brettschneider und Elena 
Schäfer danke ich für die nette Zusammenarbeit während ihrer Master- bzw. Bachelorarbeit. Darüber 
hinaus danke ich Doreen und Julius für ihren Beitrag zum gemeinsamen Review sowie für 
arbeitsrelevante Diskussionen. Julius danke ich vor allem für Ivan Mladek, für unzählige gemeinsame 
Biere, für Diskussionen, gemeinsame Wanderungen, Prag, Papa Schlumpf und das Knusperhäuschen, 
das etwas andere Sightseeing in Wien, für den gemeinsamen Besuch der Vorträge in Frankfurt, sowie 
für das freundschaftliche Verhältnis! 
Andreas Christmann danke ich für Vorschläge bezüglich der Dissertation, für die Deep Sequencing 
Projekte sowie für deren Auswertung. 
Weiterhin danke ich folgenden Mitarbeitern und ehemaligen Doktoranden des AK Kolmars, ich hoffe 
man verzeiht mir, wenn ich die ein oder andere Person aufgrund der Vielzahl an zu dankenden 
Personen vergessen habe: Bernhard Glotzbach, Caro Mai, Tim Heiseler, Alex Maass, Franzi 
Maas, Vanessa Siegmund, Sascha Knauer, Daichi Nasu, Sebastian Fabritz, Michael Reinwarth, 
Olga Avrutina. 
Ganz besonders möchte ich meiner Familie, sowie meiner zukünftigen Familie für den enormen 
Rückhalt während des Studiums und der Promotionszeit danken. Hierbei gilt mein Dank zuerst 
meinem Vater, der mich Zeit meines Lebens durchweg unterstützt hat. Der Dank hierfür ist mit 
Worten nicht zu umfassen! Danken möchte ich auch meinem Bruder Matthias sowie dessen 
Lebensgefährtin Mareen für unbeschreiblich viele Dinge, sowie ebenfalls für fachbezogene 
Gespräche. Weiterhin möchte ich Monika Conrad, Helmut Conrad sowie Christoph Conrad 
danken! Ganz besonders möchte ich meiner Freundin und Verlobten Franziska Conrad für so 
ziemlich alles und jeden gemeinsamen Moment danken: Für den besonderen Rückhalt und ihre 
Loyalität, für das Ertragen meiner Launen während des Studiums und der Promotion, für unendlich 
viele schönste Tage in meinem Leben, aber auch für das gemeinsame Überstehen schlechter Zeiten, in 
denen es ihr immer wieder gelang, meine Motivation wiederherzustellen. Im Voraus danke ich für alle 
Dinge, die uns in Zukunft noch erwarten werden!   
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Abschließend möchte ich nicht vergessen, meinen Freunden zu danken, die mich schon seit sehr langer 
Zeit begleiten. Allen voran möchte ich Max Halbritter, Jojo Lamp sowie Robert Heinz für 
unschätzbar viele und gleichermaßen wertvolle Erlebnisse und Erfahrungen danken. Zu Dank 
verpflichtet bin ich euch aus so vielen Gründen, um nur einige zu nennen: die vielen tiefsinnigen, aber 
auch stumpfsinnigen Gespräche, die unzähligen Biertouren in Frankfurt, Prag, Hamburg, Wien, 
Duisburg, Kassel, Köln, Dublin, Bremen, Los Angeles, San Diego, Las Vegas, Zürich, Paris, London 
und bald Lissabon, die gemeinsamen Wanderungen, die vielen Konzerte und Festivals, das Erweitern 
meines musikalischen Horizonts und vieles mehr. In diesem Zusammenhang möchte ich auch Reiner 
Hessler und Daniel Kind danken, die ich im Bachelorstudium an der Hochschule Darmstadt 
kennenlernen durfte und die mittlerweile zu wirklichen Freunden geworden sind. Ich danke euch nicht 
zuletzt für euren Besuch in den USA und damit verbunden für den Road Trip und das Steel Panther 
Happening in Las Vegas. Reiner danke ich darüber hinaus für Prag und zukünftig für Lissabon und 
damit verbunden für die vielen feucht-fröhlichen Momente sowie dafür, dass er sich als „Helikopter-
Landeplatz“ geopfert hat!  
